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ABSTRACT	OF	DISSERTATION	
	
	
	
EXPLORATION	OF	THE	MISUSE,	ABUSE,	AND	DIVERSION	OF	GABAPENTIN	
	
	
	 Gabapentin	is	currently	approved	by	the	Food	and	Drug	Administration	(FDA)	
as	an	adjunctive	anti-convulsant	and	an	analgesic	for	post-herpetic	neuralgia.	
Though	gabapentin	was	initially	presumed	to	have	limited	or	no	abuse	potential,	
which	may	have	contributed	to	its	widespread	off-label	prescribing,	there	have	been	
increasing	anecdotal	and	published	reports	of	its	misuse	by	substance	abusers	in	
the	community	and	penal	system.	However,	to	date,	there	has	been	limited	
systematic	evaluation	of	the	scope	and	risk	of	gabapentin	misuse	and	its	associated	
effects.	This	dissertation	assesses	the	etiology	and	prevalence	of	gabapentin	misuse,	
abuse,	and	diversion	in	a	multi-faceted	approach,	namely	by	the	individual,	
ecological,	and	pharmacoepidemiological	factors	associated	with	this	phenomenon.	
Due	to	the	importance	of	conducting	theory-driven	epidemiological	research,	this	
dissertation	uses	an	adaptation	of	the	Concurrent	Triangulation	Mixed	Method	
Multilevel	Theoretical	Model	to	guide	the	study.	Through	qualitative	analysis	of	
focus	group	data	in	an	existing	cohort	of	opioid	users,	a	systematic	review	of	peer-
reviewed	published	literature,	and	a	pharmacovigilance	assessment	of	adverse	
events	reported	to	the	FDA,	this	dissertation	describes	the	present	state	of	
gabapentin	misuse.	Findings	are	important	for	providers	and	may	help	inform	
policy	to	establish	for	whom	prescription	of	gabapentin	is	most	appropriate.		
	
	
	
KEYWORDS:	gabapentin,	substance	abuse,	theory-driven	epidemiological	research,	
mixed	method	analysis,	prescription	drug	misuse	
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CHAPTER	ONE	
Introduction	
	 Gabapentin	was	approved	in	1993	by	the	Food	and	Drug	Administration	(FDA)	
for	the	treatment	of	epilepsy	as	an	adjunct	to	anti-convulsant	therapy	and	in	2004	
was	approved	as	an	analgesic	for	post-herpetic	neuralgia.1	Gabapentin	is	an	analog	
of	GABA,2	however,	it	does	not	bind	to	GABA	receptors	(A	or	B),	but	it	can	increase	
GABA	and	can	decrease	glutamate	concentrations.3,4	One	of	its	speculated	analgesic	
mechanisms	of	action	is	that	gabapentin	may	reduce	the	release	of	pain-related	
peptides	and	may	decrease	opioid-induced	hyperalgesia.5	Because	its	exact	
mechanism	of	action	is	unclear	and	has	been	presumed	to	have	no	abuse	potential,	
gabapentin	has	been	prescribed	prolifically	off-label	for	a	vast	array	of	disorders,	
including	insomnia,	drug	and	alcohol	addiction,	anxiety,	bipolar	disorder,	borderline	
personality	disorder,	menopausal	conditions,	vertigo,	pruritic	disorders,	and	
migraines.	In	fact,	off-label	use	of	gabapentin	has	been	estimated	to	range	from	83	to	
95%	of	all	its	use,6,7	which	is	estimated	to	account	for	over	90%	of	its	sales.1	Due	to	
illegal	marketing	(i.e.,	promoting	off-label	uses)	of	gabapentin,	Pfizer	was	fined	$420	
million	after	it	was	acquired	from	Warner-Lambert.8	As	a	result,	it	has	been	
relatively	easy	to	access	gabapentin	by	prescription,	especially	since	it	has	been	
historically	opined	that	gabapentin	has	no	abuse	potential.9-13	Compounded	by	
gabapentin’s	modest,	if	not	free,	cost,14	such	factors	have	enabled	gabapentin	to	
flood	the	market	and	it	has	been	referred	to	among	the	drug	using	population	as	“a	
cheap	man’s	high”	(personal	communication).	In	a	seminal	manuscript	published	in	
American	Journal	of	Psychiatry,	Smith	et	al.	reported	a	near	3000%	increase	in	the	
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use	of	gabapentin	“to	get	high”	among	a	cohort	of	503	non-medical	prescription	
drug	users	in	Appalachian	Kentucky	from	2008	to	2014.15	Despite	these	significant	
findings,	there	has	yet	to	be	a	systematic	assessment	of	gabapentin	misuse/abuse	in	
the	general	population,	nor	within	higher-risk	subpopulations	(e.g.,	substance	abuse	
groups).	Further,	gabapentin	is	not	controlled	under	the	Controlled	Substance	Act.	
Notably,	its	close	structural	relative,	pregabalin,	was	approved	after	gabapentin	and	
is	considered	a	Schedule	V	drug,	meaning	that	it	should	be	considered	to	be	at	risk	
for	abuse	potential.16	There	is	data	suggesting	that	pregabalin	has	euphoric	and	
sedative	properties	similar	to	other	frequently	abused	substances,	that	it	can	
produce	dependence,	and	that	it	can	induce	withdrawal	symptoms	when	
discontinued.17	As	such,	because	gabapentin	and	pregabalin	presumably	have	a	
similar	mechanism	of	action,18	it	is	critical	to	systematically	study	the	abuse	
potential	of	gabapentin.	
	 The	present	study	proposes	a	multi-faceted	exploratory	evaluation	of	
gabapentin’s	abuse	potential	through	the	novel	application	of	a	peer-reviewed	
theoretical	model	that	has	been	previously	used	in	other	non-drug	related	studies.19-
22	Due	to	the	increasing	importance	of	conducting	theory-driven	epidemiological	
studies,23,24	we	will	use	an	adaptation	of	the	Concurrent	Triangulation	Mixed	
Method	Multilevel	Theoretical	Model25	(Figure	1.1)	to	inform	the	following	chapters.	
It	is	important	to	note	that	this	dissertation	is	focused	on	the	misuse,	abuse,	and	
diversion	of	gabapentin,	however,	the	methods	described	herein	are	designed	to	be	
applied	to	any	currently	used	unscheduled	drug	with	unclear	abuse	potential	(e.g.,	
quetiapine).		
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	 Throughout	the	dissertation,	the	terms	misuse,	abuse,	dependence,	and	
diversion	will	be	used	repeatedly,	thus	they	are	defined	here.	Misuse	is	defined	as	
the	use	of	a	drug	in	a	manner	or	for	a	purpose	other	than	indicated,	including,	but	
not	limited	to,	taking	another	person’s	medication,	unprescribed	or	non-
recommended	route	of	administration,	or	a	higher	dosage	than	prescribed;26	thus,	
missing	prescribed	doses	or	dose	reduction	is	not	included	in	our	definition.	Abuse	
consists	of	persistent	use	of	a	drug	despite	negative	consequences.26	Dependence	
refers	to	the	physical	and	psychological	elements	associated	with	abuse,	which	
include	compulsion,	withdrawal,	and	tolerance.26	Diversion	is	defined	as	the	
unauthorized	selling	or	sharing	of	prescription	medications,	which	can	be	either	
intentional	(e.g.,	selling	personal	medication	to	someone	without	a	prescription	for	
that	particular	drug)	or	unintentional	(e.g.,	theft).	Diversion	can	occur	at	any	point	
along	the	drug	manufacturing	and	delivery	process,	however,	at	the	core	of	this	
definition	is	unlawful	movement	of	licit	and	regulated	pharmaceuticals	to	the	illicit	
marketplace.27,28	
Concurrent	Triangulation	Mixed	Method	Multilevel	Theoretical	Model	
	 The	proposed	theoretical	model	(Figure	1.1)	was	first	introduced	by	Tashakkori	
and	Teddlie	(2003).25	The	model	can	be	broken	down	into	4	main	components.	
First,	triangulation	refers	to	“obtaining	different	but	complementary	data	on	the	
same	topic,”29	with	the	goal	of	converging	strengths	from	varying	data	types	that	
simultaneously	have	non-overlapping	weaknesses.30,31	Second,	the	data	from	each	
aim	will	be	collected	and	analyzed	concurrently,	implicitly	meaning	that	findings	
from	one	aim	will	not	influence	how	the	other	aims	are	conducted	or	analyzed.	
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Third,	both	quantitative	(QUAN)	and	qualitative	(QUAL)	methods	will	be	used	
throughout	the	proposed	study,	hence	the	mixed	method	portion	of	the	model;	
Chapters	2	and	3	will	use	both	QUAN	and	QUAL,	while	Chapter	4	will	only	use	
QUAN.	Chapter	2	will	merge	QUAL	and	QUAN	results	during	the	interpretation	
stage,	giving	equal	weight	to	each	data	type;	likewise	for	Chapter	3.	Upon	
completion	of	all	3	studies,	the	results	will	again	be	merged	with	equal	weight	to	
assess	the	abuse	potential	of	gabapentin.	Fourth,	where	the	theoretical	model	uses	
levels	of	data,	implying	a	hierarchy,	it	was	slightly	adapted	to	the	use	of	“domains,”	
or	“facets”	as	we	refer	to	them,	since	no	nesting	was	present	in	our	data.	Chapters	2,	
3,	and	4	describe	the	multi-faceted	component	of	theoretical	model	corresponding	
to	the	individual,	ecological,	and	pharmacoepidemiological	facets,	respectively.	
	 Each	of	the	proceeding	chapters	is	dedicated	to	addressing	the	following	aims:	
Aim	1/Chapter	2.	To	describe	gabapentin	misuse	at	the	individual	level	among	
existing	cohorts	of	drug	users	in	Appalachia.	
Aim	2/Chapter	3.	To	estimate	the	prevalence	and	effects	of,	motivations	behind,	and	
risk	factors	for	gabapentin	misuse,	abuse,	and	diversion	ecologically.	
Aim	3/Chapter	4.	To	evaluate	gabapentin	misuse	and	abuse	in	the	FDA	Adverse	
Event	Reporting	System	(FAERS)	using	traditional	and	innovative	
pharmacovigilance	signal	measures.		
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Figure	1.1.	Visual	depiction	of	the	modified	Concurrent	Triangulation	Mixed	Method	
Multilevel	Model.	
	
	
	
	
	
	
	
	
	
	
	
	
QUAN:	quantitative	data;	QUAL:	qualitative	data.	
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CHAPTER	TWO	
“A	cheap	man’s	high”:	a	qualitative	analysis	of	gabapentin	misuse	and	
diversion	among	drug	users	
Introduction	
	 Long	perceived	as	a	drug	with	no	abuse	potential,9,10,12	evidence	has	begun	to	
emerge	to	point	to	significant	abuse	potential	for	gabapentin.15,32	Limited	research	
has	provided	a	telescopic	snapshot	of	this	phenomenon,	with	a	prevalence	
approximation	of	1%	in	the	general	population33	and	a	much	higher	estimation	of	
15%	to	22%	in	substance	misusing	populations.15,32,34	In	the	United	States,	
gabapentin	is	currently	not	controlled	by	the	Federal	Drug	Enforcement	
Administration	(DEA),	however,	its	close	structural	relative,	pregabalin,	has	been	
classified	as	a	Schedule	V	drug,	meaning	that	it	has	abuse	potential.	While	it	appears	
that	much	of	the	misuse	is	linked	to	achieving	desirable	effects	(e.g.,	dissociation,	
euphoria,	potentiate	effects	of	drug	treatment	pharmacotherapies),32,35,36	
gabapentin	has	also	been	linked	with	impaired	driving37	and	implicated	in	1%	of	
drug	related	deaths	in	Scotland,32	highlighting	the	potential	public	health	concern	
with	gabapentin	misuse.	A	recent	review	of	international	gabapentin	misuse	and	
diversion	summarized	current	knowledge	on	this	issue38	and	highlighted	the	many	
gaps	in	our	understanding,	such	as	how	and	why	individuals	initiate	gabapentin	
misuse	and	what	are	the	factors	influencing	continued	misuse.	
	 The	purpose	of	the	present	qualitative	study	was	to	explore	such	questions	in	
the	context	of	two	samples	of	individuals	who	primarily	use	prescription	opioids	
non-medically	that	were	engaging	in	gabapentin	misuse.	A	recent	study	from	one	of	
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the	samples	noted	a	nearly	3000%	increase	from	2008	to	2014	in	gabapentin	
misuse	for	the	explicit	purpose	of	getting	“high,”	and	though	many	received	
gabapentin	from	a	prescriber,	over	a	third	obtained	it	through	drug	dealers	
indicating	its	street	value.15	Findings	will	expand	the	current	body	of	literature	on	
the	practice	of	intentional	gabapentin	misuse	and	provide	necessary	information	for	
prescribing	providers	and	regulatory	policy.	
Methods	 	
This	study	was	derived	from	longitudinal	findings	from	two	ongoing	cohort	
studies	in	Appalachian	Kentucky,	described	in	detail	elsewhere.39,40	Briefly,	the	first	
is	a	cohort	of	503	active	male	and	female	drug	users	participating	in	an	ongoing	
community-based	study	of	social	networks	and	HIV	risk	in	Appalachia.39	The	second	
is	a	cohort	of	400	rural	Appalachian	women	serving	time	in	jail	who	agreed	to	
participate	in	an	ongoing	study	examining	the	relationship	of	drug	use	and	HIV/HCV	
risk	behaviors.40	Data	from	both	studies	independently	noted	a	rapid	increase	in	the	
unintended/non-medical	use	of	gabapentin	among	their	participants.15	Thus,	the	
principal	investigators	of	each	cohort	(JRH	and	MST)	and	the	first	author	recognized	
the	necessity	of	gathering	qualitative	data	to	gain	perspective	into	this	unexpected	
rise	in	gabapentin	use.	The	present	study	presents	the	qualitative	findings	from	four	
focus	groups	conducted	among	cohort	participants	who	agreed	to	participate.	The	
University	of	Kentucky	Institutional	Review	Board	approved	the	protocol.	All	
participants	agreed	to	be	audio	recorded	and	were	compensated	for	their	time.	
Participants	
	8	
	 Individuals	were	recruited	from	two	ongoing	cohorts	of	recently	active	drug	
users	in	Appalachian	Kentucky	to	participate	in	a	focus	group	session.	Eligible	
participants	were	those	individuals	who	reported	gabapentin	use	at	their	most	
recent	follow-up	study	visit.	Research	assistants	from	both	cohort	studies	
intentionally	selected	individuals	to	approach	about	participating	in	the	focus	
groups	whom	they	felt	would	be	open	about	sharing	their	experiences.	A	total	of	33	
subjects	participated	in	the	four	focus	group	sessions.	
Data	collection	
	 Focus	groups	were	moderated	by	the	first	author	using	a	semi-structured	list	
of	questions	and	follow-up	probes.	Questions	were	developed	by	the	authors	(RVS,	
AMY,	MRL,	MST,	JRH)	drawing	on	the	current	published	and	anecdotal	knowledge	
regarding	experiences	of	gabapentin	misuse	and	were	intended	to	explore	this	
further.	Each	session	lasted	between	30	and	60	minutes	and	was	digitally	audio-
recorded.	Data	collection	was	continued	until	saturation	was	met,	which	was	after	
completion	of	4	focus	groups.	Focus	groups	were	conducted	from	March	to	
September	2015.	
Analysis	
	 Descriptive	statistics	were	derived	from	the	last	follow-up	visit	in	the	cohort	
studies.	Comparisons	were	made	using	Fisher’s	exact	tests	and	independent	
samples	t-tests.	The	audio	recording	of	each	focus	group	was	transcribed	verbatim	
by	the	authors	(RVS	and	AQ).	Two	authors	were	designated	as	readers	(RVS	and	
EMB);	each	of	whom	independently	created	a	list	of	codes	based	on	the	semi-
structured	focus	group	questions	using	a	directed	content	analysis	approach.41	The	
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readers	convened	and	discussed	these	lists	and	derived	the	initial	draft	of	the	
codebook,	which	included	codes,	sub-codes,	definitions,	and	exemplars.	The	first	
transcript	was	independently	coded	by	each	reader.	Afterward,	the	readers	again	
convened	and	reviewed	the	entire	transcript	together,	discussing	and	coming	to	a	
consensus	on	discrepant	coding	situations,	addressing	the	need	for	additional	codes	
in	the	codebook,	and	then	redefining	existing	codes.	The	first	draft	of	the	codebook	
was	subsequently	revised	and	was	used	to	code	the	next	transcript	as	well	as	re-
coding	the	first	transcript.	This	iterative	process	of	reading,	coding,	resolving	
discrepant	assignments,	revising	the	codebook,	and	re-coding	previously	coded	
transcripts	was	continued	until	all	the	data	was	coded.	SPSS	version	24	(IBM	Corp.,	
Armonk,	New	York)	was	used	to	analyze	the	quantitative	data	and	MAXQDA	
software	(VERBI	GmbH,	Berlin,	Germany)	was	used	to	analyze	the	qualitative	data.	
Several	quotes	presented	herein	were	slightly	grammatically	edited	for	readability.	
Results	
Participants	in	the	focus	groups	were	in	their	mid-thirties,	on	average,	and	the	
majority	was	unemployed	(Table	2.1).	Over	half	of	the	focus	group	subjects	from	
both	cohorts	reported	recent	(i.e.,	past	30	day)	nonmedical	use	of	prescription	
opioids	(jail	group:	73%;	community	group:	67%),	though	individuals	from	the	jail	
cohort	reported	less	drug	use	than	the	community	group	for	all	other	drug	types	
except	cocaine	(18.2	vs.	4.8%,	respectively).	Focus	group	participants	were	more	
likely	to	report	recent	nonmedical	prescription	opioid	use	compared	to	their	
respective	cohorts	(jail	cohort:	73	vs.	36%,	p	=	.02;	community	cohort:	67	vs.	41%,	p	
=	.02);	there	were	no	significant	differences	for	other	types	of	drugs.	Individuals	
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who	participated	in	the	focus	groups	were	not	significantly	different	from	other	
recent	gabapentin	users	in	their	respective	cohort	study	with	regard	to	
demographics	and	substance	use.	Based	on	information	gathered	in	the	focus	group	
sessions,	participants	varied	in	their	drug	of	abuse	preference;	several	indicated	
opioids,	others	said	cocaine,	while	still	others	noted	they	preferred	gabapentin.	
Four	main	themes,	with	subthemes,	emerged	in	the	qualitative	analysis:	(1)	
initiation,	(2)	motivation	for	continued	use,	(3)	prominence	of	gabapentin,	and	(4)	
perceptions	of	providers’	behaviors.	
Initiation	
Time	since	initiation	
The	majority	of	responses	expressed	introduction	to	gabapentin	more	than	
ten	years	ago.	Several	reported	initiation	between	5-10	years	ago	and	few	initiated	
within	the	past	two	years.	
First	source	
Prescription	from	a	doctor	for	indications	such	as	pain,	anxiety,	and	to	help	
with	opioid	detox	was	the	most	common	initial	source	of	gabapentin.	As	described	
by	one	individual:	‘That’s	how	everybody	got	introduced	to	Neurontin,	it’s	through	
doctors,	because	that’s	all	they’d	write	anybody.’	Several	others	reported	a	family	
member	or	friend	giving	gabapentin	to	them	for	the	first	time.	One	woman	
described	her	initiation	experience:	‘Well,	I	couldn’t	sleep	like	I	said.	My	mother-in-
law	gave	them	to	me	[because]	I	couldn’t	sleep	–	I	was	withdrawing	on	oxycodone	
back	then	and	couldn’t	sleep.	She	give	me	a	couple	and	I	was	out	like	a	light,	slept	
the	whole	night.	And	I	love	them	after	that.’	One	individual	noted	trying	gabapentin	
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in	the	penal	system:	‘Well	I	started	doing	it	in	federal	prison	[in]	2003,	and	been	
doing	it	ever	since.’	
Reasons	for	first	use	
Primarily	for	early	initiators	(e.g.,	more	than	5	years	ago),	many	started	
taking	gabapentin	because	their	doctor	prescribed	it	to	address	their	presenting	
symptoms,	as	this	woman	expressed:	‘I	was	put	on	it	by	a	psychiatrist	for	anxiety	in	
2005	…	that’s	what	they	prescribed	it	to	me	to	begin	with	and	I’ve	been	on	it	ever	
since	…	but	that	is	legitimately	how	it	started,	but	then	there	ain’t	no	legitimate	
reason	to	abuse	it,	you	know,	and	I	was	abusing	it.’	
Another	common	response	was	that	people	began	trying	gabapentin	due	to	
word	of	mouth.	As	one	woman	put	it:	‘I	mean	it’s	like	more	and	more	and	more	…	as	
years	went	on,	people	just	started	[gabapentin].	You’d	hear	other	people	talking	
about	taking	them,	and	I	was	like	‘well,	let	me	try	it’	[and	it]	went	from	there.’		One	
man	said,	‘[I	took	gabapentin]	on	account	of	my	cousin,	he	said	they	was	good.’	
Physical	experience	
	 Initial	experiences	with	gabapentin	included	a	range	of	effects	such	as	muscle	
relaxation,	pain	reduction,	hallucination,	sleep	induction,	feeling	drunk,	and	feeling	
‘high.’	One	woman	recounting	her	first	experience	said,	‘I	got	it	for	lupus,	but	I	had	
never	tried	it.	My	mom	actually	gave	it	to	me	first,	before	I	had	it	prescribed	to	me,	
and	made	me	high	as	all	get	out.	It	did,	and	I	was	like,	‘yes!’	{laughs}	I	didn’t	know	
anything	about	it!	It	was	new,	know	what	I	mean?’	Another	woman	described	her	
initiation:	‘I	actually	started	taking	them	to	get	off	of	drugs	because	I	was	really	in	
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pain	and	they	did	help	my	pain.	Like	she	said	they	relax	your	muscles	and	your	
bones	-	that’s	the	way	I	got	off	the	opiates.’	
Motivation	for	continued	use	
There	were	several	reasons	for	continued	use	of	gabapentin,	though	the	primary	
reason	could	be	explained	by	its	pharmacodynamic	effects.	Participants	talked	
about	gabapentin	saying	that	‘they	make	you	feel	so	much	better’	and	describing	it	
as	‘very	helpful.’	A	common	response	was	that	gabapentin	worked	better	for	easing	
pain	than	opioids.	Several	others	indicated	the	effectiveness	of	gabapentin	in	
helping	to	withdraw	from	several	substances	such	as	cocaine,	buprenorphine,	and	
oxycodone.	Though	participants	also	noted	they	could	still	get	‘high’	from	
gabapentin.	‘You	can	use	them	to	get	high	on	if	you	want	to,	ease	pain,	it’s	just	all	the	
above,’	said	one	individual,	and	another	describing	her	usage	of	gabapentin:	‘It’s	just	
the	way	an	addict	takes	them.	If	I	want	to	get	high	off	of	them,	then	I’ll	get	high	off	of	
them,	but	if	I	don’t	I	won’t.’	Several	participants	likened	a	gabapentin	high	to	one	
reminiscent	of	a	‘shot	of	cocaine’	or	an	opioid	high.	Other	effects	experienced	
included	increased	energy,	increased	appetite,	a	‘mellow’	feeling,	and	‘nodding.’		
There	tended	to	be	few	negative	effects	associated	with	gabapentin	use;	one	
woman	described	gabapentin	making	her	‘twitch’	and	several	others	indicated	
occasions	where	they	felt	like	they	were	‘smothering’	or	‘couldn’t	move,’	though	
these	were	not	their	typical	experiences	and	these	individuals	did	not	elaborate	on	
the	circumstances	surrounding	those	events	(e.g.,	dose,	concomitant	substances).	
However,	a	considerable	number	of	respondents	did	recount	painful	withdrawals	
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from	gabapentin	and	described	them	as	similar	to,	but	not	as	long-lasting	as,	opioid	
or	depressant	(e.g.,	alcohol,	alprazolam)	withdrawals.	
Participants	highlighted	the	inexpensiveness	of	gabapentin	for	the	purpose	of	
getting	high,	which	seemed	to	be	a	facilitator	for	its	continued	use.	One	participant	
said,	‘That’s	a	lot	of	reason	is	why	people	does	them	is	because	it’s	a	cheap	high,’	and	
another	noted	that	not	only	was	it	cheap,	but	nearly	‘always	available.’		
Prominence	of	gabapentin	–	current	and	trends	
	 Though	many	of	respondents	in	the	focus	groups	have	known	about	and	have	
been	using	gabapentin	for	many	years,	a	common	theme	was	noticing	its	rise	in	
popularity	in	the	community,	particularly	over	the	last	two	years.	While	the	
consensus	was	that	it	was	generally	easy	to	access	gabapentin,	there	were	also	
concerns	about	it	being	scarce	at	times	as	a	result	of	using	more	than	prescribed	and	
sharing	with	others.	To	put	the	popularity	of	gabapentin	in	perspective,	one	
individual	said,	‘They’re	actually	harder	to	find	than	30s	[roxycodone]	now,’	a	
commonly	preferred	drug	of	abuse	in	the	area.	
Interestingly,	several	individuals	observed	that	‘younger’	drug	users	(i.e.,	
adolescents)	were	choosing	gabapentin.	There	was	a	sense	that	participants	were	
feeling	their	access	is	threated	by	the	gabapentin	‘craze’:	‘And	then	…	all	these	
younger	people	are	abusing	[gabapentin]	so	now	that	puts	us	in	a	messed	up	
situation’	and	others	expressed	concern	about	gabapentin	becoming	a	scheduled	
drug,	as	one	man	stated,	‘And	that’s	why	they	[gonna]	make	them	
schedule[d]…cause	everybody’s	getting	them.’	
Perceptions	of	providers’	behaviors	–	helping	versus	barriers	
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	 There	were	mixed	reports	on	individuals’	experiences	obtaining	gabapentin	
from	a	provider	(i.e.,	physician,	pharmacist).	While	some	said	that	they	did	not	face	
any	resistance	in	obtaining	prescribed	gabapentin	from	a	provider,	others	reported	
believing	that	their	providers	made	access	to	gabapentin	more	difficult.	For	
instance,	when	asked	if	they	thought	doctors	recognized	that	people	were	using	
gabapentin	to	get	high,	several	participants	responded	‘no’	and	one	said,	‘I	don’t	feel	
like	they	do	because	they’re	still	writing	them	like	crazy.	That’s	the	one	thing	that	
they	will	write.’	Another	participant	reported	easily	getting	a	prescription	for	
gabapentin:	‘Yeah,	all	I	done	was	walk	in	and	said,	‘Hey,	I	need	some	Neurontin.’	
They’s	like,	‘What	milligram?’	I	was	like	‘800s.’’	
	 Conversely,	other	participants	reported	difficulty	in	getting	gabapentin	
prescribed	or	getting	a	prescription	filled,	saying	the	doctors	and	pharmacies	‘make	
a	bigger	deal	out	of	[gabapentin]	than	what	it	is.’	One	woman	said,	‘Tell	them	that	it	
worked	for	you	before,	and	because	of	the	Neurontin,	gabapentin	epidemic,	they’re	
calling	it,	they	won’t	write	them	for	you.’	Another	reported:	
‘I	have	been	to	doctor	X	and	he	give	me	everything	under	the	sun,	and	I	went	
there	trying	to	get	Neurontins.	Did	this,	dealt	with	this	man	for	six	months,	
and	he	still	would	not	come	off	with	the	Neurontin	–	not	one.’		
Still	another	woman	described	a	recent	pharmacy	visit	to	pick	up	her	gabapentin	
prescription:	
‘I	went	on	a	Saturday	and	I	was	like,	‘I	thought	it	was	my	day	to	get	
[gabapentin]’	and	the	lady	was	like,	‘you	can	come	back	Monday	to	get	them.’	
Well,	I	went	back	Monday.	‘Well	I	can’t	give	them	to	you.’	And	I	was	like,	‘no,	
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you	told	me	to	come	back	Monday.’	I	said,	‘I	can’t	be	coming	up	here,	coming	
to	get	my	medicine.’	And	she	said,	‘well,	ok.	I’ll	go	ahead	and	do	it	for	you.’	
And	then	they	give	me	my	blood	pressure	medicine,	too,	and	I	said,	‘man,	
hold	up.	I	just	got	the	blood	pressure	medicine	last	week’	…	I	handed	[the	
blood	pressure	medicine]	back.’	
Discussion	
	 The	current	study	aimed	to	help	characterize	and	explain	the	observed	
recent	rise	in	gabapentin	misuse	by	conducting	a	qualitative	analysis	of	focus	group	
data	among	males	and	females	who	abuse	drugs	in	rural	Appalachia.	This	study	
explored	constructs	that	influence	or	prohibit	gabapentin	misuse	among	
Appalachian	drug	users.		
	 The	individuals	participating	in	this	study	were	more	likely	to	report	recent	
nonmedical	prescription	opioid	use	than	their	cohort	counterparts	that	did	not	
participate	in	the	focus	groups,	though	focus	group	participants	were	not	different	
from	their	cohort	counterparts	that	also	reported	gabapentin	use.	Others	have	also	
recently	observed	the	correlation	between	opioid	and	gabapentin	use.15,32,34,42	There	
are	a	number	of	hypotheses	as	to	why	this	association	may	occur	such	as	common	
co-prescription	of	gabapentin	with	opioids	for	pain	patients,38	using	gabapentin	to	
potentiate	the	effects	of	opioid-use	treatment	to	achieve	a	‘high,’32	or	user	
substitution	of	harder	to	access,	more	expensive	prescription	opioids	for	
gabapentin.42	These	speculations	would	be	well	served	by	controlled	experiments,	
particularly	of	pharmacological	nature,	to	further	explore	the	relationship	between	
opioids	and	gabapentinoids.	
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	 Many	participants	reported	initiating	gabapentin	after	receiving	a	
prescription	from	their	doctor.	Though	it	may	be	possible	that	some	individuals	
were	prescribed	gabapentin	for	one	of	its	two	FDA-approved	usages	(i.e.,	adjunctive	
therapeutic	for	epilepsy	or	analgesic	for	post-herpetic	neuralgia),	it	appears	as	
though	the	majority	were	prescribed	for	an	off-label	indication	(e.g.,	treatment	of	
anxiety,	non-herpetic	pain,	and	drug	withdrawal).	Because	of	the	consequences	of	
the	opioid	epidemic,	there	have	been	large-scale	efforts	focused	on	reducing	opioid	
prescribing.	In	the	2016	guidelines	for	chronic	pain	opioid	prescribing	produced	by	
the	Centers	for	Disease	Control	and	Prevention	(CDC),	an	entire	section	was	
dedicated	to	pharmacologic	alternatives	to	opioids	for	pain	management,	in	which	
gabapentin	was	recommended	as	a	first-line	treatment.43	So,	even	though	there	are	
signals	emerging	that	gabapentin	may	have	abuse	potential,	it	seems	that,	overall,	
policy	makers	and	prescribers	are	unaware	and	under	the	impression	it	is	safe	to	
prescribe,	particularly	for	neuropathic	pain.	Unfortunately,	since	gabapentin’s	
market	release	in	1993,	there	have	been	no	further	experiments	in	the	human	
laboratory	to	reassess	and	quantify	its	abuse	liability,	which	is	especially	important	
among	high-risk	populations	such	as	drug	users.	Because	there	is	clear	evidence	
(also	echoed	by	focus	group	participants	in	the	present	study)	that	gabapentin	has	
central	nervous	system	and	psychoactive	effects,15,32,36,38,44	and	potential	to	alleviate	
opioid45	and	benzodiazepine46	withdrawal,	there	is	a	discernible	justification	to	
examine	whether	or	not	gabapentin	is	appropriately	labeled	and	controlled.	
	 We	also	observed	reports	that	younger	people	were	misusing	gabapentin.	
Due	to	the	high	saturation	of	gabapentin	in	the	community	as	a	result	of	liberal	
	17	
prescribing	practices,	it	would	be	incredibly	easy	for	someone	to	access	it,	though	
demand	seems	to	limit	diverted	access.	This	begs	the	question	–	are	young	drug	
users/adolescents	initiating	prescription	drug	abuse	with	gabapentin?	Further,	does	
use	of	gabapentin	among	this	population	lead	to	use	of	other,	more	harmful	
prescription	or	illicit	drugs?	Though	these	are	merely	questions	to	consider;	the	
observation	shared	by	several	long-term	drug	users	raises	enough	alarm	to	warrant	
investigation	of	gabapentin	misuse	among	the	younger	population.	
Several	limitations	exist	in	the	present	study.	It	is	unclear	the	extent	to	which	
interpersonal	dynamics	influenced	what	was	shared	within	the	focus	groups.	
Difficulty	in	analyzing	such	data	can	arise	particularly	when	an	individual	
dominated	a	session	or	when	a	normative	view	of	gabapentin	use	was	formed	
within	the	group.47	However,	these	concerns	were	at	least	somewhat	mitigated	by	
highlighting	diverse	voices	within	the	analysis.	Further,	we	conducted	multiple	
focus	groups	in	different	locations	(both	community	and	jail	settings)	and	found	the	
same	themes	emerging	throughout,	giving	support	for	the	reliability	and	validity	of	
our	findings.	The	study	was	conducted	in	rural	Appalachian	Kentucky	among	
individuals	already	participating	in	research	studies,	thus	generalizability	may	be	
limited,	although	it	should	be	noted	that	this	is	one	area	of	the	country	where	
signals	of	the	impending	prescription	opioid	epidemic	first	began.	Additionally,	the	
focus	group	members	were	people	who	were	willing	to	speak	about	their	
experience	and,	therefore,	may	not	be	representative	of	all	gabapentin	users	in	the	
parent	studies.	
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Despite	limitations,	this	study	provides	a	valuable	in-depth	look	into	the	
experience	of	gabapentin	misuse	within	a	sample	that	has	the	only	hypothesized	
risk	factor	for	it:	a	history	of	or	current	substance	(i.e.,	opioid)	abuse.48,49	It	is	
necessary	for	prescribers	to	understand	how	individuals	begin	and	continue	their	
misuse	of	gabapentin	and	to	focus	on	prescribing	only	for	those	individuals	for	
whom	it	is	properly	indicated.	Our	findings	also	underscore	the	necessity	of	more	
rigorous	studies	to	elucidate	the	abuse	potential	of	gabapentin,	as	well	as	a	
thoughtful	consideration	of	its	scheduling.	
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Table	2.1.	Sociodemographic	characteristics	and	drug	use	behaviors	of	focus	group	
participants	and	their	cohort	counterparts.	
	
Jail	
cohor
t	–	FG		
(n=11
)	
Jail	
cohort	
–	GBP	
users	a	
(n=101
)	
Jail	
cohortb	
(n=393
)	
Communit
y	cohort	–	
FG	
(n=21)c	
Communit
y	cohort		-	
GBP	
usersa	
(n=157)	
Communit
y	cohortb	
(n=361)	
Sociodemographic	
characteristics	
	 	 	 	 	 	
Age	–	mean	(SD)	
median	(IQR)	
35.3	
(8.4)	
35.0	
(15.0)	
35.5	
(8.5)	
34.0	
(12.5)	
34.3	
(8.2)	
33.0	
(11.0)	
32.1	
(10.3)	
39.0	
(15.0)	
39.3	(8.9)	
39.0	
(12.5)	
38.1	
(8.4)*	
37.0	
(11.0)	
Employment	
status	
	 	 	 	 	 	
Employedd	 3	
(27.3)	
10	
(10.0)	
79	
(20.1)	
1	(4.8)	 42	(26.7)*	 115	
(31.8)	
Unemployed	 7	
(63.8)	
68	
(67.4)	
271	
(68.9)	
13	(61.9)	 69	(43.9)*	 143	
(39.6)	
Recent	drug	use	 	 	 	 	 	 	
Alcohol	to	
intoxication	
2	
(18.2)	
17	
(16.8)	
37	
(9.4)	
21	(100)	 156	
(99.4)	
358	
(99.2)	
Heroin	 0	
(0.0)	
11	
(10.9)	
26	
(6.6)	
20	(95.2)	 151	
(96.8)	
352	
(97.8)	
Prescription	
opioids		
8	
(72.7)	
58	
(57.4)	
140	
(35.6)*	
14	(66.7)	 85	(54.1)	 148	
(41.0)*	
Legal	
buprenorphine		
0	
(0.0)	
18	
(17.8)	
38	
(9.7)	
1	(4.8)	 10	(6.4)	 15	(4.2)	
Illicit	
buprenorphine		
1	
(9.1)	
46	
(45.5)	
93	
(23.7)	
3	(14.3)	 49	(31.2)	 67	(18.6)	
Benzodiazepines		 3	
(27.3)	
57	
(56.4)	
122	
(31.0)	
7	(33.3)	 66	(42.0)	 98	(27.1)	
Cocaine	 2	
(18.2)	
19	
(18.8)	
39	
(9.9)	
1	(4.8)	 22	(14.0)	 38	(10.5)	
Methamphetami
ne		
2	
(18.2)	
32	
(31.7)	
92	
(23.4)	
20	(95.2)	 153	
(98.1)	
356	
(98.9)	
Marijuana	 4	
(36.4)	
51	
(50.5)	
121	
(30.8)	
21	(100)	 154	
(98.7)	
355	
(98.6)	
SD:	standard	deviation;	IQR:	interquartile	range;	GBP:	gabapentin.	FG:	focus	group.	
Note:	recent	drug	use	is	defined	as	any	use	in	the	past	30	days;	comparisons	were	
made	between	the	focus	group	participants	and	(1)	other	GBP	users	from	their	
cohort	and	(2)	the	rest	of	their	cohort	(including	other	GBP	users).	
aIndividuals	from	the	cohort	that	reported	recent	gabapentin	use,	but	did	not	
participate	in	a	focus	group.	
	20	
bAll	cohort	members	excluding	those	that	participated	in	a	focus	group.	
cOne	participant	did	not	complete	quantitative	survey.	
dIncludes	full	and	part	time	work.	
*p	<	.05
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CHAPTER	THREE	
Gabapentin	misuse,	abuse,	and	diversion:	A	systematic	review	
Introduction	
Gabapentin	is	an	analog	of	GABA	2;	however,	it	does	not	bind	to	GABAA	or	
GABAB	receptors	(or	benzodiazepine,	opioid	or	cannabinoid	receptors),	but	it	can	
increase	GABA	and	can	decrease	glutamate	concentrations	3,4.	Its	mechanisms	of	
antiepileptic	and	analgesic	actions	are	unknown,	although	some	have	speculated,	in	
the	case	of	the	latter,	that	gabapentin	may	reduce	the	release	of	pain-related	
peptides	and	may	decrease	opioid-induced	hyperalgesia	5.	However,	a	unique	
gabapentin	binding	protein	has	been	identified	50,51	as	a	subunit	of	the	voltage-
dependent	calcium	channel	complex	52,	suggesting	a	less	specific	mechanism	of	
action	through	modulation	of	neurosignaling.	
Gabapentin	was	approved	in	1993	by	the	US	Food	and	Drug	Administration	
(FDA)	initially	only	for	treatment	of	epilepsy	as	an	adjunct	to	anticonvulsant	
therapy,	but	in	2004	was	also	approved	as	an	analgesic	for	post-herpetic	neuralgia	1.	
The	European	Medicines	Agency	approved	gabapentin	in	2006	for	epilepsy	and	
certain	types	of	neuropathic	pain	53	and	the	UK	National	Institute	for	Clinical	
Excellence	(NICE)	recommends	gabapentin	as	a	first-line	treatment	for	all	
neuropathic	pain	54.	Because	its	mechanism	of	action	is	unclear	and	it	is	assumed	to	
have	no	abuse	potential,	gabapentin	is	widely	used	off-label	to	treat	an	array	of	
disorders,	including	insomnia,	various	neuropathic	pain	conditions,	drug	and	
alcohol	addiction,	anxiety,	bipolar	disorder,	borderline	personality	disorder,	
menopausal	conditions,	vertigo,	pruritic	disorders,	and	migraines.	In	fact,	estimates	
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of	the	off-label	usage	of	gabapentin	are	reported	to	range	from	83-95%	of	all	
gabapentin	use	6,7,	which	is	estimated	to	account	for	over	90%	of	its	sales	1.	Due	to	
illegal	marketing	(promoting	off-label	uses)	of	gabapentin,	Pfizer	was	fined	$420	
million	after	it	was	acquired	from	Warner-Lambert	8.	
Gabapentin	is	safely	tolerated	over	a	very	broad	range	of	doses	from	
approximately	800-1800	mg/day	(although	package	inserts	suggest	that	patients	
may	be	treated	with	doses	as	high	as	3600	mg/day).		In	clinical	practice,	dosing	is	
typically	titrated	starting	from	lower	doses	(i.e.,	<400	mg/day)	and	moving	rapidly	
upward.	The	European	Medicines	Agency	55	and	the	Physician	Prescribing	
Information	generally	recommends	dosing	up	to	1800	mg	in	adults.	While	
substantially	higher	doses	have	been	tested	in	clinical	trials,	no	additional	clinical	
benefit	has	been	observed	56.	However,	other	studies	have	examined	gabapentin	as	
acute	doses	in	the	higher	dose	range,	and	it	was	well	tolerated.	At	least	one	imaging	
study	has	reported	that	gabapentin	(1200	and	2400	mg)	significantly	(and	rapidly)	
increased	measurable	concentrations	of	brain	gamma-aminobutryric	acid	(GABA),	
one	of	its	presumed	mechanisms	of	action	4.	Hart	and	colleagues	(2004)	examined	
gabapentin	(600	and	1200	mg)	for	its	potential	to	reduce	the	reinforcing	effects	of	
cocaine	in	the	human	laboratory	57.	Their	data	reveal	reductions	in	ratings	of	anxiety	
with	both	gabapentin	doses	(in	the	absence	of	cocaine)	compared	to	placebo.	Lile	
(2013)	examined	600	and	1200	mg	yielding	significant	differences	from	placebo	on	
numerous	outcomes,	including	liking,	take	again	and	good	effects	58.	Bisaga	and	
Evans	(2006)	examined	gabapentin	in	combination	with	alcohol	at	acute	doses	of	
1000	and	2000	mg	59.	In	this	dose	range,	gabapentin	produced	some	direct	effect	on	
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psychomotor	function	but	was	still	safely	tolerated	in	combination	with	alcohol.	
Despite	initial	views	that	gabapentin	had	no	abuse	potential	9-13,	there	have	
been	numerous	published	case	reports	of	gabapentin	abuse	by	substance	abusers	in	
the	community	and	penal	system	35,44,60-70.	The	purpose	of	this	review	is	to	describe	
the	international	scope	of	gabapentin	abuse	(i.e.,	prevalence,	risk	factors,	
motivations	behind	misuse,	how	it	is	misused,	illicit	value,	effects	experienced)	and	
to	identify	implications	for	practice	and	future	research.	
Methods	
Definitions	
	 The	definitions	presented	here	were	used	to	guide	article	selection	and	are	
used	throughout	the	present	article	to	facilitate	discussion.	Gabapentin	refers	to	the	
capsules,	tablets,	and	oral	solutions	of	which	gabapentin	(1-
(aminomethyl)cyclohexaneacetic	acid)	is	the	active	ingredient.	This	definition	
includes	the	prodrug	of	gabapentin,	gabapentin	enacarbil.	When	discussing	case	
reports,	the	dose	and	formulation	of	gabapentin	will	be	specified,	when	that	
information	is	available.	Misuse	is	defined	as	the	use	of	a	drug	in	a	manner	or	for	a	
purpose	other	than	indicated,	including,	but	not	limited	to,	taking	another	person’s	
medication,	unprescribed	or	non-recommended	route	of	administration,	or	a	higher	
dosage	than	prescribed	26;	thus,	missing	prescribed	doses	or	dose	reduction	is	not	
included.	Abuse	consists	of	persistent	use	of	a	drug	despite	negative	consequences	
26.	Dependence	refers	to	the	physical	and	psychological	elements	associated	with	
abuse,	which	include	compulsion,	withdrawal,	and	tolerance	26.	Diversion	is	defined	
as	the	unauthorized	selling	or	sharing	of	prescription	medications,	which	can	be	
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either	intentional	(e.g.,	selling	personal	medication	to	someone	without	a	
prescription	for	that	particular	drug)	or	unintentional	(e.g.,	theft).	Diversion	can	
occur	at	any	point	along	the	drug	manufacturing	and	delivery	process,	however,	at	
the	core	of	this	definition	is	unlawful	movement	of	licit	and	regulated	
pharmaceuticals	to	the	illicit	marketplace	27,28.	
Search	strategy	and	article	selection	
	 This	review	sought	to	identify	peer-reviewed,	published	manuscripts	
describing	cases	of	gabapentin	misuse	and/or	abuse	in	accordance	with	Preferred	
Reporting	Items	for	Systematic	Review	and	Meta-Analyses	(PRISMA)	guidelines.	
The	databases	PubMed,	Web	of	Science	(all	databases),	CINAHL,	PsycINFO,	and	
Cochrane	were	searched	utilizing	terms	and	strategies	specific	to	each	database	
(Appendix	A)	developed	in	collaboration	with	a	qualified	librarian	and	peer-
reviewed	by	two	additional	medical	librarians.	All	searches	were	conducted	
between	May	and	August	2015.	Only	those	articles	written	in	English	that	described	
occurrences	of	gabapentin	misuse/abuse	among	human	populations	were	included.	
Studies	describing	only	gabapentin	toxicity,	withdrawal,	or	dependence	without	
misuse/abuse	were	excluded,	as	were	articles	describing	only	pregabalin	
misuse/abuse.	Grey	literature,	as	defined	by	the	Institute	of	Medicine	71,	was	
excluded;	a	well-constructed	preliminary	examination	in	Google	Scholar	provided	
over	21,000	results,	exclusion	of	which	highlighted	a	vast	body	of	evidence	of	
gabapentin	misuse.	Snowball	sampling	(i.e.,	reviewing	references	of	included	
papers)	was	then	used	to	identify	any	additional	articles	that	may	have	been	
excluded	after	applying	index-based	filters.	
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	 Data	extraction	was	performed	by	the	first	author;	all	of	the	selected	articles	
were	reviewed	by	the	second	and	third	authors	to	assess	whether	they	met	
inclusion	criteria.	Any	disagreements	regarding	inclusion	were	discussed	among	all	
authors	until	agreement	was	reached.	
Results	
The	initial	search	yielded	1,128	unique	citations,	of	which	1,067	were	excluded	
based	on	title	or	abstract	(Figure	3.1).	Sixty-one	articles	were	read	in	their	entirety	
to	assess	whether	they	met	inclusion	criteria.	Thirty	were	excluded	because	they	did	
not	actually	describe	gabapentin	misuse,	abuse,	or	diversion.	The	remaining	31	
articles	met	all	inclusion	criteria.	Snowball	sampling	identified	351	unique	
publications;	346	were	excluded	based	on	title	or	abstract,	2	met	criteria	and	were	
included	in	the	review.	In	total,	this	systematic	review	analyzed	33	articles.	There	
were	47	case	studies	of	gabapentin	misuse/abuse	found	in	23	published	articles	
from	1993	to	2015	and	11	epidemiological	reports	published	over	the	same	time	
frame	(one	article	described	both	types	37).	Notably,	one	review	article	was	included	
in	this	paper	not	due	to	the	content	of	the	review,	but	rather	a	statement	in	the	
introduction,	which	mentioned	a	personal	communication	of	large-scale	gabapentin	
abuse	occurring	within	a	drug	using	population	in	Pittsburgh,	Pennsylvania	62.		
The	present	review	attempted	to	summarize	rigorously	conducted	and	well-
presented	findings	on	gabapentin	misuse/abuse.	As	such,	the	quality	of	case	reports	
could	not	be	evaluated;	therefore,	this	presentation	focused	on	epidemiological	and	
toxicological	studies	using	case	studies	as	secondary	data.	It	would	be	detrimental	
to	have	excluded	case	reports,	as	they	provide	rich	context	from	which	the	
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population	data	may	arise.	Therefore,	unless	clearly	noted	in	the	manuscript	text	
that	the	article	was	a	case	report,	the	reader	could	assume	that	the	study	was	
sample-based.	
Study	base	and	data	sources	
The	11	epidemiological	studies	(all	cross-sectional)	selected	for	this	analysis	
obtained	data	from	unique	sources	(Table	3.1);	four	publications	involved	substance	
misuse/abuse	populations	15,32,34,72,	two	examined	toxicology	records	37,73,	one	used	
a	population-based	sample	33,	two	involved	reports	to	a	poison	center	74,75,	and	two	
analyzed	websites	with	qualitative	information	regarding	gabapentin	abuse	36,76.	
Over	half	of	the	case	report	articles	(n=14)	arose	from	patients	presenting	to	
a	hospital	or	general	clinic	with	overdose	or	withdrawal-like	symptoms	
60,61,64,67,68,70,77-84;	two	came	from	substance	abuse	clinics	62,66,	three	from	psychiatric	
facilities	44,63,69,	two	from	the	penal	system	35,65,	one	from	postmortem	toxicology	
findings	85,	and	one	from	poison	center	reports	75.	
Demographic	and	geographical	distribution	
Five	epidemiology/toxicology	papers	provided	demographic	characteristics	
of	their	sample.	Two	toxicology	studies	using	poison	center	data	indicated	slightly	
higher	representation	of	females	(60-65%)	74,75,	while	another	study	among	opioid	
dependent	patients	found	no	significant	difference	in	representation	by	gender	
(51%	male,	p=0.58)34.	One	article	noted	that	females	were	significantly	more	likely	
to	misuse	gabapentin	than	males	in	a	cohort	of	opioid	users	(percent	
difference=17.3%,	95%	confidence	interval=10.4-24.6%)	15.	A	toxicology	paper	by	
Peterson	(2009)	observed	no	difference	in	gender	in	the	likelihood	of	being	a	
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positive	gabapentin	driving	impairment	case	(50%	male)37.	Among	case	studies,	
males	had	slightly	higher	representation	than	females	(15	males	vs.	13	females),	
although	gender	was	incompletely	specified	in	two	reports	66,75.	The	mean	age	of	
samples	ranged	between	21	and	43	in	studies	in	which	it	was	reported	34,37,73-75.	The	
calculated	mean	age	of	case	reports	was	41.		
Published	reports	came	from	the	United	States	(67%,	n=22),	the	United	
Kingdom	(12%,	n=4),	Germany	(3%,	n=1),	Finland	(3%,	n=1),	India	(3%,	n=1),	
South	Africa	(3%,	n=1),	France	(3%,	n=1),	and	two	analyzed	websites	not	specific	to	
a	particular	country	(6%).	While	all	of	the	articles	in	this	review	described	
gabapentin	misuse/abuse,	12	(36%)	were	documented	reports	of	overdose	
involving	gabapentin	60,61,67,74,75,78-82,84,85.	
Misuse	and	abuse	of	gabapentin	
Prevalence.	Only	one	article	gave	an	estimate	of	lifetime	prevalence	of	
gabapentin	abuse	in	the	general	population;	Kapil	and	colleagues	(2013)	surveyed	a	
UK	population-based	sample	of	1500	and	found	that	1.1%	reported	ever	misusing	
gabapentin	33.	
Over	half	of	the	studies	described	gabapentin	misuse	that	occurred	among	
samples	with	a	history	of	or	current	substance	misuse/abuse/dependence	(n=6),	
the	majority	of	which	discussed	opioid	misuse,	specifically	(n=5).	Smith	(2012)	and	
Baird	(2013)	gave	reports	of	gabapentin	misuse	within	Scottish	populations	that	
attended	substance	misuse	clinics,	which	likely	included	individuals	who	abuse	
alcohol	and/or	drugs	32,72.	Recent	cross-sectional	studies	of	opioid	abuse	samples	in	
the	US	and	UK	estimated	gabapentin	misuse	to	be	between	15-22%	15,32,34	and	
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gabapentin	abuse	with	a	prescription	ranged	from	40-65%	15,33,34,75.	There	was	little	
evidence	of	gabapentin	abuse	among	those	with	a	positive	history	of	alcohol	abuse	
or	dependence.	In	fact,	Wilens	and	colleagues	(2015)	conducted	a	survey	among	
opioid	dependent	individuals	seeking	substance	detoxification	in	the	US	and	found	
no	gabapentin	abuse	among	those	undergoing	alcohol	detoxification	34.	Conversely,	
for	opioid	dependent	patients,	40%	reported	using	more	gabapentin	than	
prescribed	and	13%	reported	using	unprescribed	gabapentin	34.	
In	Scotland	in	2010,	approximately	1%	of	all	drug-related	deaths	were	
directly	attributed	to	gabapentin	32.	Further,	two	articles	assessed	toxicological	
results	in	primarily	substance	misusing	populations;	the	first	examined	23,479	
impaired	driving	cases	in	the	US	and	found	gabapentin	was	involved	in	0.6%	of	
them	37,	while	a	Finnish	study	reviewed	13,766	medico-legal	postmortem	
investigations	and	identified	gabapentin	in	0.3%	of	the	cases	73.	
Doses,	Cost,	and	Diversion.	Studies	indicate	gabapentin	is	misused/abused	
over	a	wide	range	of	doses,	from	within	therapeutic	range	(900-3600	mg/day)	to	
supratherapeutic	doses.	All	but	two	articles	discussed	the	dosage	involved	in	
gabapentin	misuse	32,33.	Evidence	from	the	US	suggested	that	gabapentin	misuse	
among	individuals	with	prescriptions	for	gabapentin	involved	a	higher	amount	than	
prescribed	34,73,86.	For	example,	as	previously	mentioned,	a	US	study	found	that	22%	
of	a	sample	of	162	opioid-dependent	patients	had	a	prescription	for	gabapentin,	of	
which	40%	indicated	they	used	more	than	prescribed	34.	Potential	explanations	for	
this	trend	are	tolerance	and	addiction	as	described	in	two	clinical	case	discussions	
from	France	and	the	US,	respectively	44,70.	Interestingly,	according	to	American	and	
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European	case	reports,	those	who	used	gabapentin,	but	did	not	have	a	prescription	
for	it,	often	took	doses	that	fell	within	clinical	guidelines,	regardless	of	motivations	
behind	use,	though	the	doses	were	not	spread	out	over	the	course	of	a	day	and	it	
was	unclear	how	often	an	individual	dosed	per	day	66,68.	
Over	half	of	the	articles	(n=7)	mentioned	or	referred	to	diversion	of	
gabapentin.	Studies	in	the	UK	and	US	identified	health	services/physicians	as	one	of	
the	major	sources	of	misused	gabapentin,	with	rates	ranging	from	52-63%	(the	63%	
also	may	include	baclofen	and	pregabalin)	15,33.	Other	sources	included	family	or	
acquaintances,	Internet,	bought	abroad	33,	and	drug	dealers	15.	
Case	reports	support	these	findings	from	epidemiological	studies.	Reports	
from	India,	the	UK	and	US	also	identify	family	members	or	acquaintances	as	
gabapentin	sources.	Behaviors	that	are	markers	of	abuse	liability,	such	as	doctor	
shopping,	exaggeration	of	symptoms,	and	fabrication	of	prescriptions,	were	
reported	in	case	studies	from	France	and	the	US	66,70.	Due	to	widespread	gabapentin	
abuse	in	a	US	correctional	facility,	Reccoppa	and	colleagues	(2004)	inventoried	
dispensed	medications	and	found	only	19	of	96	prescriptions	in	the	possession	of	
the	inmate	receiving	the	prescription	65.	
There	is	a	street	market	demand	for	gabapentin.	An	American	case	study	
stated	that,	“{gabapentin}	tablets	were	sometimes	sold	or	traded	for	illicit	drugs”	66.	
In	Scotland,	the	Drug	and	Crime	Enforcement	Agency	identified	the	growing	use	of	
gabapentin	as	a	cutting	agent	in	heroin	72.	In	the	UK	and	US,	epidemiological	studies	
reported	the	illicit	market	value	for	gabapentin	ranged	from	<1-7	USD	per	pill	
depending	on	strength	15,32,72.	
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Combination	with	other	substances.	Three	toxicology	studies	elucidated	the	
most	commonly	found	substances	with	gabapentin.	The	first,	by	Häkkinen	and	
colleagues	(2014),	examined	Finnish	postmortem	toxicological	samples	positive	for	
gabapentin	from	2010-2011	and	found	that	all	cases	classified	as	gabapentin	abuse	
also	involved	the	use	of	alcohol	and/or	opioids	(most	commonly	buprenorphine	and	
tramadol)	73.	Peterson	(2009)	conducted	a	study	in	the	US,	also	utilizing	
toxicological	data,	which	examined	the	presence	of	gabapentin	in	driving	
impairment	cases.	Only	7%	of	gabapentin-positive	blood	samples	detected	solely	
gabapentin;	the	remainder	were	polysubstance	cases,	with	benzodiazepines	(44%),	
opioids	(43%),	antidepressants	(43%),	other	CNS	depressants	(e.g.,	trazodone,	
zolpidem;	36%),	antiepileptics	(25%),	cannabinoids	(15%),	stimulants	(11%),	and	
ethanol	(6%)	37.	Smith	and	colleagues	(2012)	stated	that	postmortem	toxicology	
reports	in	Scotland	revealed	75%	of	those	identifying	gabapentin	also	included	
morphine	and/or	methadone,	which	the	authors	said	may	be	indicative	of	recent	
opioid	dependence	72.	The	toxicology	studies,	while	helpful	for	providing	a	picture	of	
what	classes	of	medicines	were	commonly	found	in	combination	with	gabapentin,	
did	not	address	unprescribed	mixing	of	licit	or	illicit	drugs.	
Alternatively,	several	epidemiological	studies	did	identify	simultaneous	
combination	of	gabapentin	with	other	substances	for	the	explicit	purpose	of	
misusing	them.	One	article	discussed	the	misuse	of	gabapentin	in	combination	with	
buprenorphine	for	the	purpose	of	“getting	high”	15.	Similarly,	Baird	and	colleagues	
(2014)	stated	that	38%	of	a	substance	misuse	sample	in	Scotland	took	gabapentin	
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(and/or	pregabalin)	in	combination	with	prescribed	methadone	to	potentiate	the	
effects	of	methadone	32.		
Studies	in	US	and	UK	substance	abuse	populations,	by	Smith	(2015)	and	
Smith	(2012)	respectively,	identified	a	greater	likelihood	for	those	misusing	
gabapentin	to	also	be	misusing	prescription	opioids	15,72.	Smith	(2015)	also	found	
that	individuals	who	reported	using	gabapentin	to	get	“high”	were	also	more	likely	
to	be	misusing	benzodiazepines	15,	which	supports	the	finding	by	Peterson	(2009;	
discussed	earlier)	that	benzodiazepines	were	the	most	commonly	detected	class	of	
drugs	in	combination	with	gabapentin	37.	
Use	of	gabapentin	and	ethanol	were	commonly	reported	together;	in	addition	
to	the	two	toxicology	studies	discussed	earlier	37,73,	another	mentioned	the	misuse	
of	gabapentin	in	combination	with	alcohol	36.	An	international	review	of	recreational	
gabapentin	misuse	anecdotes	described	other	substances	that	have	been	reported	in	
conjunction	with	misused	gabapentin	including	cannabis,	SSRIs,	LSD,	amphetamine,	
and	GHB	(gamma-Hydroxybutyric	acid)	36.	
Case	studies	have	corroborated	the	epidemiological	findings	and	have	also	
identified	buprenorphine/naloxone	and	quetiapine	as	combinations	of	abuse	with	
gabapentin	35,66,76.	
Motives.	A	variety	of	motivations	behind	gabapentin	misuse	were	identified,	
many	that	related	to	substance	abuse	behaviors	in	general,	which	included:	
recreational	use	15,32,36,72,	control	mood	and/or	anxiety	37,	potentiate	the	effects	of	
drug	abuse	treatment	32,	and	intentional	self	harm	75.	Case	reports	substantiated	
those	intentions	35,44,61,63-69,76,78,82,84,85,	and	also	identified	the	following:	pain	77,	
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reduce	cravings	for/manage	withdrawal	from	other	drugs	63,64,69,	substitute	for	
other	drugs	35,63,66,	and	addicted	to	gabapentin	44,70.	
Effects	Experienced.	Only	three	epidemiological	studies	mentioned	the	
effects	sought	by	misusing	gabapentin	32,36,72;	these	findings	were	not	presented	as	
inference	from	a	sample,	rather	examples	accumulated	from	individual	reporting.	
Six	case	reports	also	described	feelings	achieved	from	gabapentin	misuse/abuse	
35,63-66,69.	Therefore,	the	two	types	of	articles	were	combined	in	this	section	to	
provide	a	comprehensive	catalog	of	individual	effects	experienced	and	consequently	
should	be	interpreted	with	caution.	
Several	case	studies	mentioned	experiencing	euphoria	after	gabapentin	
misuse	that	was	reminiscent	of,	but	not	as	strong	as,	opioids	35,66,69.	This	feeling	was	
achieved	in	combination	with	other	drugs	(e.g.,	buprenorphine/naloxone,	
methadone,	baclofen,	quetiapine,	alcohol)	32,35,36,66	as	well	as	by	using	gabapentin	
alone	69,72,	in	dosages	ranging	from	1500-12000	mg,	though	only	three	articles	give	
actual	amounts	misused	35,66,69.	One	case	study	described	individuals	snorting	
gabapentin	powder	from	capsules	and	experiencing	a	high	similar	to	that	felt	after	
snorting	cocaine	65.	Another	commonly	reported	sensation	from	gabapentin	misuse	
was	sedation/relaxation/calmness,	which	was	described	in	six	studies	35,36,63,64,66,72.	
As	with	euphoria	achieved	from	gabapentin	misuse,	sedation/relaxation/calmness	
was	experienced	in	combination	with	other	substances	(e.g.,	quetiapine,	alcohol,	
cannabis,	buprenorphine/naloxone)	35,64,66	or	by	taking	gabapentin	alone	36,63,	and	
over	a	range	of	dosages	(e.g.,	600-4800	mg).	Other	effects	experienced	included:	
improved	sociability	36,72,	marijuana-like	“high”	36,72,	cocaine-like	“high”	65,	
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“amphetamine	rush”	36,	disassociation	36,	MDMA-like	“high”	36,	increased	energy	and	
focus	69,	improved	quality	of	sleep	69,		and	becoming	more	talkative	36.	
Discussion	
Gabapentin	has	been	presumed	to	have	no	abuse	potential	historically	9-13,	
however,	this	review	reports	evidence	to	the	contrary.	Of	the	11	population-based	
studies	and	23	case	reports	included	here,	nearly	one-third	report	gabapentin	
misuse/abuse	for	recreational	purposes	and	epidemiological	studies	from	the	US	
and	UK	estimate	abuse	rates	between	40-65%	just	among	individuals	with	a	
gabapentin	prescription.	Studies	from	the	UK	indicate	that	gabapentin	has	
developed	a	prominent	place	as	a	drug	of	abuse;	in	Scottish	prisons,	gabapentin	is	
among	the	top-requested	prescription	drugs	of	abuse	32.	However,	the	rise	in	
popularity	of	recreationally	used	gabapentin	is	occurring	in	the	US,	as	well.	Smith	
and	colleagues	(2015)	describe	a	near	3000%	increase	in	the	use	of	gabapentin	to	
get	“high”	from	2008	to	2014	among	a	cohort	of	503	prescription	drug	users	in	the	
Central	Appalachian	region	of	the	US	15.		
Motivations	for	misused	gabapentin	can	be	classified	largely	into	three	basic	
categories:	recreational	(e.g.,	get	high	or	substitute	for	more	expensive	drugs),	self-
harm,	and	self-medication	(e.g.,	for	pain	or	withdrawal	symptoms	from	other	
substances).	The	majority	of	case	reports	involved	individuals	who	had	
prescriptions	for	gabapentin,	but	took	higher	dosages	than	they	were	prescribed.	
Descriptive	reports	on	gabapentin	reveal	an	array	of	subjective	experiences	
evocative	of	opioids	(e.g.,	euphoria,	talkativeness,	increased	energy,	sedation),	
benzodiazepines	(e.g.,	sedation),	and	psychedelics	(e.g.,	dissociation).	These	effects	
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do	not	appear	to	be	specific	to	a	particular	dose	and	may	occur	well	within	the	
therapeutic	range.	No	pattern	was	observed	in	terms	of	dose	taken	or	interactions	
between	dose	and	motive	or	dose	and	effects	achieved,	which	may	be	partially	
explained	by	the	unpredictable	pharmacokinetics	and	non-linear	bioavailability	of	
gabapentin	87.	To	date,	no	carefully	controlled	human	laboratory	studies	have	been	
published	that	sought	to	examine	and	characterize	the	abuse	potential	profile	of	
gabapentin	in	comparison	to	other	prototypic	drugs	of	abuse.		Overall,	further	
empirical	research	is	clearly	needed	to	better	evaluate	and	characterize	gabapentin	
psychopharmacology	and	the	risks	associated	with	gabapentin	use,	especially	
among	those	using	it	recreationally.	
It	is	difficult	to	ascertain	risk	factors	for	gabapentin	misuse/abuse	except	
history	of	or	current	drug	abuse,	particularly	opioids,	is	likely	one	from	reports	
available	to	date.	While	no	studies	to	date	have	formally	assessed	a	history	of	or	
current	substance	abuse	(especially	drug	abuse)	as	a	risk	factor	for	gabapentin	
misuse,	it	was	the	most	common	characteristic	detected	here.	This	is	particularly	
important	because	it	indicates	that	the	increasing	trend	in	gabapentin	abuse,	
notably	among	populations	with	opioid	misuse,	has	the	potential	to	affect	an	
estimated	0.6-0.8%	of	the	world’s	population	aged	15-64	that	has	used	opioids	in	
the	past	year	88.	It	is	important	to	note,	however,	that	this	review	may	overrepresent	
individuals	who	have	abused	substances,	illustrating	the	importance	of	examining	
gabapentin	misuse	in	the	general	population.	Further,	grey	literature	was	excluded,	
which	may	have	provided	more	information	from	which	to	infer	risk	factors	for	
misuse,	along	with	other	characteristics	of	gabapentin	misuse/abuse.	Still,	the	
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present	review	emphasizes	the	paucity	of	peer-reviewed	research	on	this	important	
emerging	topic,	and	provides	key	starting	points	for	subsequent	examination.	
Gabapentin	is	relatively	inexpensive	and,	in	fact,	many	individuals	can	
acquire	it	for	free	or	a	drastically	reduced	price	under	subsidy	plans	14,89,90.	Further,	
due	to	its	widespread	off-label	prescribing	worldwide	1,6,7,	it	is	relatively	easy	to	
receive	gabapentin	by	prescription,	as	illustrated	by	physicians	and	the	health	care	
system	being	the	primary	source	of	misused	gabapentin	in	the	US	and	UK.	These	
factors	have	enabled	the	market	to	be	flooded	with	gabapentin	and	it	has	been	
referred	to	among	the	drug	using	population	as	“a	cheap	man’s	high”	(personal	
communication).	It	is	important	that	prescribers	recognize	the	current	diversion	of	
gabapentin	and	dispense	judiciously.	
Gabapentin	requires	a	prescription,	but	generally	has	no	additional	controls	
90-93;	however,	pregabalin,	its	close	structural	relative,	which	was	approved	after	
gabapentin,	was	placed	into	Schedule	V	(abuse	potential)	in	the	US	16	and	included	
in	the	European	Monitoring	Centre	for	Drugs	and	Drug	Addiction	(EMCDDA)-
Europol	annual	report	on	new	psychoactive	substances	of	abuse	94.	It	was	found	that	
pregabalin	had	euphoric	and	sedative	properties	similar	to	other	frequently	abused	
substances;	moreover,	as	it	is	known	that	tolerance	and	physical	dependence	(with	
withdrawal	symptoms	upon	discontinuation)	may	occur	in	response	to	repeated	
dosing,	these	factors	may	contribute	to	the	escalation	or	continued	misuse	of	
gabapentin	in	those	abusing	the	drug	for	its	psychoactive	effects	17.	Our	review,	and	
other	non-abuse	reports	falling	outside	the	scope	of	this	study	95-101,	identified	that	
gabapentin,	too,	produces	these	effects	(i.e.,	tolerance,	physical	dependence,	and	
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withdrawal)	thereby	warranting	reevaluation	of	its	abuse	potential.	However,	it	is	
important	to	consider	in	reexamination	that	gabapentin	may	be	an	appropriate	
treatment	for	many	individuals	(e.g.,	those	in	alcohol	withdrawal,	chronic	pain,	
epilepsy)	that	may	face	impediments	to	receiving	their	medication	upon	increased	
control.	Therefore,	a	risk-benefit	analysis	is	necessary	prior	to	any	abuse	potential	
labeling.	
From	published	reports	presented	here,	gabapentin	is	most	often	misused	in	
combination	with	other	substances,	especially	opioids,	benzodiazepines,	and	
alcohol,	although	details	in	this	area	are	sparse	and	necessitate	systematic	data	
collection	and	analysis.	Concomitant	use	is	particularly	important	because	
gabapentin	is	often	co-prescribed	with	opioids,	and	pain	patients	often	receive	
prescriptions	for	benzodiazepines	due	to	anxiety	and/or	difficulty	sleeping.	
Moreover,	its	uncontrolled	status	leads	doctors	to	believe	that	it	lacks	abuse	
potential;	thus,	they	may	feel	confident	in	their	prescribing	of	gabapentin	to	patients	
with	substance	use	histories.	NHS	England	released	advice	for	gabapentin	
prescribers	that	strongly	recommends	using	it	as	approved,	offering	alternative	
interventions	for	conditions	outside	the	licensing	indications	93.	Finally,	
benzodiazepines	have	been	used	to	treat	delirium	resulting	from	gabapentin	
withdrawal	64	and	gabapentin	has	been	used	to	treat	withdrawal	from	both	
benzodiazepines	46	and	alcohol	9,11.	These	findings	suggest	that	these	three	agents	
may	share	a	common	neuropharmacological	pathway	for	abuse	and	dependence;	
however,	further	research	is	necessary	to	explore	this	hypothesis.	
	37	
In	summary,	findings	from	the	present	review	suggest	that	gabapentin	is	
misused/abused	internationally	for	recreation,	self-medication,	or	self-harm,	with	
an	array	of	subjective	experiences.	Substance	abuse	populations,	especially	
individuals	with	a	history	of	or	current	opioid	misuse,	appear	to	be	at	particular	risk	
for	misuse/abuse.	Further	studies	to	identify	risk	factors	for	gabapentin	misuse	and	
to	characterize	gabapentin’s	abuse	liability	are	recommended.	
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Table	3.1.	Summary	of	gabapentin	misuse	in	reviewed	articles	
Study,	
year,	
and	
refere
nce	
Cou
ntry	
Type	of	
study	
Sample	
size	
and	
charact
eristics	
Prevale
nce	of	
gabape
ntin	
misuse
/abuse	
Dose	 Cost,	
Source,	
Diversio
n	
Other	
substances	in	
simultaneous	
combination	
Motives	 Effects	
experien
ced	
Route	
of	
adminis
tration	
Baird		
2013	
(42)	
Scotl
and	
Paper	
survey	
N=129	
from	
six	
substa
nce	
misuse	
clinics	
19%	 Not	
mentio
ned	
Not	
mention
ed	
Methadone;	
possibly	
benzodiazepine
s	
To	
become	
intoxicate
d,	to	
potentiat
e	the	
effects	of	
methado
ne	
Feeling	
‘high’	or	
‘stoned’	
Not	
mentio
ned	
Hakki
nen	
2014	
(46)	
Finl
and	
Analysi
s	of	
toxicolo
gical	
autopsi
es	
N=22,4
21	
medico
-legal	
autopsi
es	with	
toxicol
ogy	
sample
s;	8	
cases	
of	
gabape
ntin	
abuse;	
75.0%	
of	
gabape
ntin	
abuse	
cases	
were	
male;	
median	
age	of	
gabape
ntin	
abuse	
cases	
(range)
:	30	
(24-
47)	
0.31%	
involve
d	in	
postmo
rtem	
cases;	
18%	of	
those	
were	
related	
to	drug	
abuse	
For	
abuse	
cases,	
median	
concen
tration	
in	
postmo
rtem	
femora
l	blood:	
12	
mg/L	
(range
=0.62-
45)	
Not	
mention
ed	
Alcohol	(37.5%	
of	gabapentin	
abuse	cases);	
opioids	(87.5%	
of	gabapentin	
abuse	cases)	
Not	
mentione
d	
Not	
mention
ed	
Not	
mentio
ned	
Kapil		
2013	
(47)	
UK	 Online	
survey	
N=150
0	
market	
researc
h	panel	
membe
rs;	
49.1%	
male;	
9.1%	
age	16-
20,	
40.5%	
age	21-
39,	
21.1%	
age	40-
49,	
29.3%	
1.1%	
lifetim
e	
prevale
nce	
Not	
mentio
ned	
57.8%	
received	
from	
family	or	
acquaint
ances;	
47.3%	
from	the	
Internet;	
7.8%	
abroad	
Not	mentioned	 Not	
mentione
d	
Not	
mention
ed	
Not	
mentio
ned	
	39	
age	50-
59	yo	
Klein-
Schwa
rtz	
2003	
(49)	
USA	 Analysi
s	of	
poison	
control	
cases	
N=20	
gabape
ntin	
exposu
res	
reporte
d	to	
three	
poison	
control	
centers
;	60%	
female;	
mean	
age	for	
asympt
omatic	
cases	
(±	SD):	
21.8	±	
29.0;	
mean	
age	for	
sympto
matic	
cases	
(±	SD):	
23.0	
±13.9	
20	of	
77	
gabape
ntin-
involve
d	cases	
were	
gabape
ntin-
only	
Mean	
dose	(±	
SD)	for	
asympt
omatic	
cases:	
1906	
mg	
±2238;	
mean	
dose	
for	
sympto
matic	
cases:	
6320	
mg	
±1092
6	
65%	
involved	
the	
patient’s	
own	
medicati
on	
52	of	77	cases	
involved	co-
ingestants,	but	
did	not	specify	
what	they	were	
and	were	
excluded	from	
analysis	
55%	was	
intention
al	suicide	
attempt;	
5	cases	of	
therapeut
ic	error;	4	
unintenti
onal	
(general)	
cases	
Drowsin
ess	(x8),	
ataxia	
(x2),	
tachycar
dia	(x2),	
dizzines
s	(x3),	
hypoten
sion	
(x2),	
nystagm
us	(x1),	
nausea/
vomiting	
(x2),	
diarrhea	
(x1),	
syncope	
(x1),	
bradycar
dia	(x1),	
none	
(x5)	
Not	
mentio
ned	
Peters
on	
2009*	
(41)	
USA	 Analysi
s	of	
blood	
sample
s	
N=23,4
79	
driving	
impair
ment	
cases	
in	
Washin
gton	
state	
from	
2003-
2007;	
50%	
male;	
mean	
age	(±	
SD):	
43.0	
±10.9	
0.6%	
were	
positiv
e	for	
gabape
ntin	
Mean	
concen
tration	
(±SD):	
8.4	
mg/L	
±5.4;	
median
:	7.0	
Not	
mention
ed	
Only	9	of	the	
gabapentin	
cases	were	
positive	for	
gabapentin	
only.	Of	the	
remainder,	
44%	also	
contained	
benzodiazepine
s,	43%	opioids,	
antidepressants	
43%,	other	CNS	
depressants	
36%,	
antiepileptic	
drugs	25%,	
15%	
cannabinoids,	
11%	
stimulants,	and	
6%	ethanol.	
Not	
mentione
d	
Not	
mention
ed	
Not	
mentio
ned	
Schifa
no	
2011	
(50)	
Onli
ne	
revi
ew	
Qualitat
ive	
analysi
s	of	
website
s	
N=108	
websit
es	in	
English
,	
Germa
n,	
Spanis
h,	
Italian,	
Dutch,	
Norwe
gian,	
Finnish
,	and	
Not	
mentio
ned	
Varyin
g	doses	
mentio
ned	in	
subject
ive	
reports	
rangin
g	from	
900	to	
4800	
mg	
Mention
ed	
online	
pharmac
ies	as	a	
source,	
but	
likely	
not	sole	
source	
Baclofen,	
cannabis,	
alcohol,	SSRIs,	
LSD,	
ampthetamine,	
GHB	
Not	clear,	
but	likely	
recreatio
nal	use	
Reminis
cent	of	
“amphet
amine	
rush,”	
“fully	
sedated	
opiate	
buzz,”	
“disasso
ciation	
like	
DXM,”	
“talkativ
e,”	
Oral	
and	
intram
uscular	
	40	
Swedis
h	
“compar
able	to	
cannabis
,”	“buzz	
slightly	
reminisc
ent	of	
MDMA”	
Seale	
2014	
(51)	
Onli
ne	
revi
ew	
Brief	
summa
ry	of	
website	
finding
s	
Drug	
forums	
and	
pharm
acist	
blogs	
Not	
mentio
ned	
Not	
mentio
ned	
Not	
mention
ed	
Buprenorphine
/naloxone	
To	get	
“high”	
Not	
mention
ed	
Not	
mentio
ned	
Smith	
2012	
(43)	
Scotl
and	
-
Qualitat
ive	
reports	
-
Prescri
bing	
data		
-
Clinical	
data	-
Postmo
rtem	
examin
ations	
-
Qualita
tive	
reports	
arose	
from	
from	
clinical	
experie
nces	
and	a	
police	
report,	
unrepo
rted	
sample	
size	
-
Prescri
bing	
data:	
arose	
from	
Taysid
e	
region	
in	
Scotlan
d	from	
1993-
2011,	
unrepo
rted	
sample	
size	
-
Clinical	
data	
arose	
from	
substa
nce	
misuse	
service
s	in	
Taysid
e,	
Scotlan
d	in	
2009,	
n=251	
of	
those	
who	
Of	251	
individ
uals	in	
substa
nce	
misuse	
clinics,	
5.2%	
receivi
ng	
prescri
bed	
gabape
ntin;	Of	
1400	
postmo
rtem	
toxicol
ogy	
examin
ations,	
48	
include
d	
gabape
ntin,	of	
which	
36	also	
include
d	
methad
one	
and/or	
morphi
ne	
The	
5.2%	
receivi
ng	
prescri
ption	
gabape
ntin	
have	a	
mean	
dose	of	
1343	
mg	
Can	
purchas
e	on	the	
street	
market	
for	
approxi
mately	1	
GBP	per	
300	mg;	
gabapen
tin	is	
being	
used	as	
a	cutting	
agent	in	
heroin	
accordin
g	to	a	
police	
report	
Nonmedical	use	
of	prescription	
analgesics,	
morphine,	
methadone	
Not	clear,	
but	likely	
recreatio
nal	use	
Euphori
a,	
improve
d	
sociabilit
y,	a	
marijuan
a-like	
‘high’,	
relaxatio
n,	sense	
of	calm,	
‘zombie-
like’	
effects	
Not	
mentio
ned	
	41	
had	
used	
misuse	
service
s	for	4+	
years	
-
Postmo
rtem	
examin
ations	
came	
from	
Central
,	
Taysid
e,	and	
Fife	
Scotlan
d	in	
2011,	
n=140
0	
Smith	
2015	
(44)	
USA	 Questio
nnaire	
N=503	
nonme
dical	
prescri
ption	
opioid	
users	
from	
2008	
to	
2014;	
77.8%	
of	
gabape
ntin	
misuse	
cases	
were	
female	
15%	in	
past	6	
months	
Not	
mentio
ned	
Physicia
ns	
(52%)	
and	drug	
dealers	
(36%);	
costs	
less	than	
1	USD	
per	pill	
Unclear	if	
simultaneous	
use,	but	were	
more	likely	
than	non-
gabapentin	
users	to	report	
past	30-day	use	
of:	immediate-
release	
oxycodone,	
buprenorphine,	
benzodiazepine
s	
Recreatio
nal,	“to	
get	high”	
Not	
mention
ed	
Not	
mentio
ned	
Wilen
s	2015	
(45)	
USA	 Survey	 N=162	
opioid	
depend
ent	
patient
s	
seeking	
detoxifi
cation;	
51%	
male;	
mean	
age	
(±SD):	
33	
(±10)	
22%	
receive
d	
prescri
ption	
gabape
ntin;	
40%	of	
which	
reporte
d	using	
more	
than	
prescri
bed;	
13%	
used	
unpres
cribed	
gabape
ntin;	in	
total,	
22%	
misuse
d	
gabape
Not	
mentio
ned	
Not	
mention
ed	
Not	mentioned	 Not	
mentione
d	
Not	
mention
ed	
Not	
mentio
ned	
	42	
ntin	
(either	
more	
than	
prescri
bed	or	
taking	
unpres
cribed)	
Wills		
2014	
(48)	
USA	 Medical	
chart	
review	
N=347	
poison	
center	
reports
;	69.5%	
female;	
median	
age	
(IQR):	
30	(20-
44)	
116	
cases	
of	
gabape
ntin	
overdo
se	
Median	
dose:	
6000	
(IQR:	
2700-
12000)	
Not	
mention
ed	
Co-ingestion	
cases	were	
excluded	
Not	
mentione
d	
10%	
neurom
uscular	
sympto
ms,	2%	
seizures,	
41%	
CNS	
sympto
ms,	6%	
GI	
sympto
ms,	11%	
cardiac	
sympto
ms,	16%	
blood	
pressure
,	5%	
metaboli
c	signs	
Not	
mentio
ned	
Case	Reports	
Study,	
year,	
and	
refere
nce	
Cou
ntry	
Gender	
and	age	
History	
of	
substan
ce	
abuse	
Dose	 Cost	 Source/
Diversio
n	
Other	
substances	in	
simultaneous	
combination	
Motives	 Effects	
experien
ced	
Route	
of	
adminis
tration	
Barru
eto	
2002	
(52)	
USA	 34	yo	
male	
No	 8000	
mg/da
y	
Not	
mentio
ned	
Patient’s	
own	
medicati
on	
None	 Manage	
pain	
Withdra
wal	
Presum
ed	oral,	
but	not	
explicit
ly	
mentio
ned	
Cantre
ll	
2015	
(24)	
USA	 47	yo	
female	
Yes	(D)	 Up	to	
15.6	g	
once	
Not	
mentio
ned	
Daughte
r’s	
medicati
on	
None	 Not	clear	 Death	 Oral	
Ferna
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*Article	is	a	mixed	methods	analysis	of	qualitative	and	quantitative	data.	Therefore,	
this	article	appears	in	both	the	first	and	second	sections	of	this	table.	**Article	
described	4	cases,	only	one	of	which	may	have	been	gabapentin	misuse	and	is	
therefore	the	only	incident	included	in	summary.	***Article	combined	information	
for	5	cases.	
A	=	alcohol	abuse;	CNS	=	central	nervous	system;	D	=	drug	abuse;	DXM	=	
dextromethorphan;	GBP	=	British	pound;	GHB	=	4-hydroxybutanoic	acid;	GI	=	
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gastrointestinal;	IQR	=	interquartile	range;	LSD	=	lysergic	acid	diethylamide;	MDMA	
=	3,4-methylenedioxyamphetamine;	SD	=	standard	deviation;	SSRIs	=	selective	
serotonin	reuptake	inhibitors;	USD	=	United	States	dollar.	
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CHAPTER	FOUR	
Drug	misuse	signals	in	gabapentin:	a	pharmacovigilance	assessment	using	the	
FDA	Adverse	Event	Reporting	System	
Introduction	
	 Gabapentin	is	approved	by	the	United	States	Food	and	Drug	Administration	
(FDA)	for	post-herpetic	neuralgia	and	as	an	anti-epileptic,	but	is	often	used	off	label	
(e.g.,	for	non-herpetic	pain,	mood	disorders)	and	is	currently	being	investigated	as	a	
pharmacotherapeutic	for	alcohol	withdrawal.	In	the	latest	guidance	report	for	pain	
prescribing,	the	Centers	for	Disease	Control	(CDC)	suggested	gabapentin	as	a	first	
line	medication	for	treating	chronic	pain.102	Since	its	market	release	in	1993,	
gabapentin	has	been	touted	as	having	no	abuse	potential,	which	has	likely	led	to	its	
prolific	off	label	prescribing.	In	fact,	it	has	been	estimated	that	between	83-95%	of	
all	gabapentin	prescriptions	are	for	a	non-approved	usage.6,7	However,	since	the	
first	published	report	of	gabapentin	misuse	in	1994,61	a	significant	number	of	
accounts	of	gabapentin	misuse	and	abuse	have	followed.	A	recent	systematic	review	
identified	23	published	case	studies	and	epidemiological	reports	of	gabapentin	
misuse/abuse	from	seven	different	countries.38	
	 Evidence	on	the	prevalence	of	gabapentin	misuse	has	been	limited.	A	single	
study	has	estimated	the	population	prevalence	of	gabapentin	misuse	as	1%	in	the	
United	Kingdom.33	However,	3	studies	have	estimated	the	prevalence	of	gabapentin	
misuse	within	substance	misuse	samples	in	the	United	States	and	the	United	
Kingdom	between	15-22%,15,32,34	a	number	which	apparently	is	increasing	as	more	
drug	users	become	aware	of	the	desirable	effects	of	gabapentin	[personal	
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communication].	How	gabapentin	produces	analgesic	and	anticonvulsant	effects	is	
unknown,	though	it	likely	interacts	with	calcium	channels	to	reduce	
neurotransmitter	release	in	the	central	nervous	system	neuronal	tissues.87	There	is	
a	wide	spectrum	of	the	subjective	effects	of	gabapentin,	particularly	when	not	used	
as	intended	(e.g.,	larger	doses	than	prescribed),	including:	dissociation,	euphoria,	
sedation/relaxation/calmness,	elevated	mood,	disinhibition,	delirium,	feeling	“high”,	
and	feeling	drunk.35,36,66,69	
	 Without	definitive	controlled	pharmacological	studies	to	reassess	
gabapentin’s	abuse	potential,	we	must	look	to	available	data	to	estimate	the	
presence	and	risk	of	gabapentin	misuse	in	a	timely	manner.	One	such	resource	is	the	
FDA	Adverse	Event	Reporting	System	(FAERS),	a	publicly	available,	regularly	
maintained	database.	In	the	United	States,	postmarketing	adverse	events	(AEs)	
associated	with	any	drug	or	biologic	product	can	be	reported	to	the	FDA	through	
their	passive	surveillance	program	called	FAERS.	Approximately	5%	of	AEs	reported	
to	FAERS	are	generated	voluntarily	by	health	professionals	(e.g.,	physicians,	
pharmacists,	nurses)	and	consumers	(e.g.,	patients,	family	members,	lawyers),	who	
can	submit	AEs	via	the	online	submission	system	called	MedWatch.103	The	other	
95%	of	FAERS	reports	come	from	voluntary	AE	reporting	to	the	drug	sponsor	or	
manufacturer,	who	is	then	required	to	forward	the	report	on	to	the	FDA.103	The	
Center	for	Drug	Evaluation	and	Research	(CDER),	a	subsidiary	of	the	FDA,	monitors	
reports	and	follows	up	with	further	evaluation	on	concerns	identified	through	
FAERS.104	If	findings	indicate	drug	or	product	safety	concern,	the	FDA	can	choose	to	
take	regulatory	action,	including,	but	not	limited	to:	updating	labeling	information,	
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restricting	use,	communicating	safety	information	to	the	public,	or	removing	from	
the	market.104	To	date,	FAERS	has	received	over	12	million	reports,	two	million	of	
those	from	2016	alone.103	
Pharmacovigilance	(PhV),	which	is	the	collection,	study,	detection,	and	
prevention	of	drug	adverse	events,	is	a	useful	tool	for	hypothesis-generation	or	
hypothesis-support	of	drug-AE	pairs,	though	it	is	prerequisite	to	have	a	theoretical	
conceptualization	of	the	drug-AE	combination	one	intends	to	investigate.105	PhV	
studies	typically	use	several	assessment	measures	to	detect	a	“signal”	for	a	
particular	drug.106	A	signal	is	a	previously	unknown	possible	causal	association	of	
an	adverse	event	resulting	from	taking	a	drug.107	Signals	are	disproportionality	
measures	based	on	a	2x2	contingency	table	(Table	4.1)	and	determine	whether	a	
drug-AE	pair	is	occurring	more	often	than	expected	by	comparing	signal	values	to	
published	thresholds.108-111		
This	study	will	use	the	FAERS	database	to	calculate	signal	measures	for	
reporting	of	gabapentin	and	abuse-related	AEs	(AR-AEs)	and	compare	these	
findings	to	a	negative	and	positive	control.	The	AR-AEs	of	interest	will	be	selected	a	
priori	based	on	effects	experienced	with	gabapentin	misuse	according	to	current	
body	of	literature.36,38	However,	signals	of	misuse/abuse/addiction	may	not	be	
identified	through	observation	of	a	single	AE	at	a	time	(e.g.,	report	of	gabapentin	and	
ataxia	doesn’t	necessarily	indicate	abuse).	Rather,	it	may	be	more	useful	to	examine	
joint	occurrence	of	several	AEs	that	are	indicative	of	drug	misuse/abuse/addiction.	
Therefore,	in	addition	to	the	traditional	signal	measures,	this	study	will	use	a	novel	
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application	of	loglinear	modeling	to	assess	the	frequency	of	concurrent	reporting	of	
AEs	associated	with	gabapentin	misuse/abuse.	
Methods	
Data	source	
All	FAERS	quarterly	data	from	January	1,	2004	to	December	31,	2015	were	
downloaded	from	the	FDA	website,112	however,	since	pregabalin	was	not	approved	
by	the	FDA	until	December	30,	2004,113	data	from	2004	were	excluded.	Each	
quarterly	data	set	contained	7	data	files:	(1)	patient	demographic	and	
administrative	information;	(2)	drug/biologic	information	for	as	many	medications	
as	were	reported	for	the	event;	(3)	all	Medical	Dictionary	for	Regulatory	Activities	
(MedDRA)114	terms	coded	for	the	adverse	event;	(4)	patient	outcomes	for	the	AE;	
(5)	report	sources	for	the	AE;	(6)	drug	therapy	start	and	end	dates	for	the	reported	
drug(s);	and	(7)	all	MedDRA	terms	for	the	indications/diagnoses	for	use	for	the	
reported	drug(s).115	For	the	purposes	of	this	analysis,	only	the	demographic,	drug,	
and	reaction	data	tables	were	used.	
	 We	used	positive	and	negative	controls	to	compare	our	gabapentin	findings.	
Pregabalin,	a	structural	cousin	of	gabapentin	with	a	theoretically	similar	mechanism	
of	action,	has	been	classified	as	a	Schedule	V	drug	because	of	its	abuse	potential,	
which	made	it	an	ideal	candidate	for	the	positive	control.	Duloxetine,	a	serotonin-
norepinephrine	reuptake	inhibitor	(SNRI),	has	been	recommended	as	a	first	line	
medication	for	the	treatment	of	neuropathic	pain43	(gabapentin	is	also	
recommended	as	a	first	line	treatment43)	due	to	its	efficacy	and	because	it	is	rarely	
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associated	with	substance	use	disorder,	thus	it	was	selected	it	as	the	negative	
control.	
	 Based	on	the	proposed	methodology	of	Moore	et	al.	(1997),	a	case/non-case	
approach	was	used,	where	each	drug-AE	pair	of	interest	denoted	a	case	and	all	other	
possible	pairs	as	non-cases.116	In	every	FAERS	AE	drug	file,	role	codes	had	been	
assigned	to	each	reported	drug	and	indicated	as	follows:	primary	suspect	drug	(PS),	
secondary	suspect	drug	(SS),	interacting	(I),	or	concomitant	(C).	Often,	only	PS,	SS,	
and	I	medications	are	considered	as	cases.	However,	several	have	raised	concerns	
about	excluding	C	medications	as	cases,	particularly	if	it	is	an	unexpected	drug-AE	
association.	As	explained	in	the	EudraVigilance	data	analysis	guidelines,	“In	our	
case,	it	is	quite	often	the	case	that	drug-event	associations	are	not	commonly	
established	until	knowledge	of	the	potential	signal	[is]	available.”117	Therefore,	due	
to	the	historic	opinion	that	gabapentin	had	no	abuse	liability	it	was	apt	to	include	
cases	where	gabapentin	(and	pregabalin	and	duloxetine)	was	listed	as	a	
concomitant	medication.	
Case	identification	-	drugs	
	 Drug	cases	(i.e.,	AE	reports	[AERs]	which	included	gabapentin,	pregabalin,	
and/or	duloxetine)	were	identified	in	the	FAERS	drug	table	using	a	fuzzy	matching	
algorithm.	First,	medication	names	in	the	FAERS	file	were	truncated.	The	SAS	
SOUNDEX	procedure	was	employed	to	identify	potential	drug	case	matches	by	both	
brand	and	generic	name	of	the	case	drugs.	The	SOUNDEX	procedure	works	through	
phonetic	matching	and	can	help	reduce	the	effect	of	variations	in	spelling.118-120	The	
potential	matches	identified	through	the	fuzzy	matching	algorithm	were	manually	
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scanned	by	the	first	author	to	determine	whether	or	not	it	was	a	true	case.	Only	
matches	with	a	frequency	of	five	or	more	were	considered	eligible	to	be	cases.	SAS	
version	9.4	(Cary,	North	Carolina)	was	used.	
Data	cleaning	
Each	AER	in	FAERS	has	a	unique	“ISR	number,”	which	can	be	used	to	link	
files	across	all	seven	data	tables.	A	Case	number	also	identifies	an	AER,	however,	it	
may	encompass	several	ISR	numbers	(AERs)	due	to	follow-up	reporting	for	the	
same	event.	Once	the	drug	files	were	merged	with	their	corresponding	demographic	
files	by	ISR	number,	the	AER	in	each	Case	ID	series	with	the	most	recent	date	was	
kept,	according	to	FAERS	cleaning	protocol,121	and	duplicates	were	removed.	The	
demographic/drug	file	was	then	merged	with	the	MedDRA	AE	file	by	the	ISR	
number.	
Case	identification	-	AEs	
	 Using	a	variety	of	sources122-124	we	created	a	list	of	MedDRA	preferred	terms	
(PT)	that	were	explicit	indications	of	abuse	(e.g.,	drug	diversion,	drug	addiction)	and	
those	that	could	be	indicative	of	abuse	(e.g.,	ataxia,	falls,	euphoric	mood,	
dissociation).	Here	abuse-related	will	be	used	to	incorporate	both	explicit	abuse	
MedDRA	terms,	as	well	as	MedDRA	terms	that	are	possible	indicators	of	abuse.	The	
list	was	reviewed	by	well-qualified	individuals	(pharmacologist	[SLW]	and	
psychiatrist	[MRL})	and	revised	until	a	final	list	was	agreed	upon	by	the	authors.	
The	48	selected	abuse-related	MedDRA	terms	included:	addiction;	aggression;	
ataxia;	confusional	state;	delirium;	delusion;	dependence;	disorientation;	
dissociation;	dizziness;	drug	abuse;	drug	abuser;	drug	addict;	drug	dependence;	
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drug	diversion;	drug	tolerance;	drug	withdrawal	syndrome;	euphoric	mood;	
elevated	mood;	fall;	feeling	abnormal;	feeling	drunk;	feeling	of	relaxation;	gait	
disturbance;	hallucination;	hallucination,	auditory;	hallucination,	visual;	
hallucination,	mixed;	incoherent;	intentional	(drug)	misuse;	intentional	overdose;	
intoxication;	mood	altered;	multiple	drug	overdose;	off	label	use;	overdose;	
prescription	drug	use	without	a	prescription;	psychosis;	acute	psychosis;	rebound	
psychosis;	substance	induced	psychosis;	transient	psychosis;	somnolence;	
substance	abuse;	substance	abuser;	substance	use;	thinking	abnormal;	tolerance	
increased.	The	terms	addiction,	drug	addict,	intoxication,	prescription	drug	use	
without	a	prescription,	psychosis,	transient	psychosis,	and	tolerance	increased	had	
no	associated	AERs,	and	were	excluded	from	further	analysis.	It	should	be	noted	
that	each	AER	could,	and	most	often	did,	include	more	than	one	MedDRA	term.	
Signal	calculation	
	 Since	AE	reporting	can	be	affected	by	many	external	factors,	cumulative	
signal	measures	were	calculated,105	that	is,	data	were	aggregated	over	the	11-year	
study	period	rather	than	calculated	quarterly.	Descriptive	statistics	were	calculated	
for	each	drug-AR-AE	pair.	Traditional	signal	measures	consisted	of	the	proportional	
reporting	ratio	(PRR),109	reporting	odds	ratio	(ROR),111	the	information	
component,108	and	the	empirical	Bayesian	geometric	mean	(EBGM).110	Published	
criteria	for	each	signal	measure	are	as	follows:105	
PRR:	n≥3,	PRR≥2,	χ2≥4;	
ROR:	lower	limit	of	95%	confidence	interval	>	1;	
IC:	lower	limit	of	two-sided	95%	credible	interval	>	0;	
	55	
EBGM:	n>0,	lower	one-sided	95%	credible	interval	>	2.	
First,	a	composite	AR-AE	variable	was	created,	that	is,	any	AER	that	reported	at	least	
one	of	the	41	AR-AEs	was	coded	as	1	and	those	AERs	that	did	not	were	coded	as	0.	
Signal	measures	were	calculated	for	each	drug-composite	AR-AE	pair.	Then	signal	
measures	were	calculated	for	individual	AR-AE-drug	pairs.	The	traditional	signal	
measures	differ	in	their	sensitivity	and	specificity.	Therefore,	we	decided	that	for	
our	purposes,	a	drug-AE	pair	would	be	significant	if	all	four	signal	measures	met	the	
thresholds	described	above.	The	R	package,	PhVid,125	was	used	to	obtain	all	signal	
scores.		
Loglinear	analysis	
	 Loglinear	models	allow	for	the	simultaneous	examination	of	the	association	
between	more	than	two	categorical	variables,	essentially	an	extension	of	the	2x2	
contingency	table	to	a	2x2x…x2	table,	particularly	useful	when	there	is	more	than	
one	response	variable.	This	type	of	model	can	describe	the	joint	distribution	of	any	
number	of	K	categorical	factors.		
	 First,	a	composite	abuse-specific	(AS-AE)	variable	was	created	where	any	AER	
that	reported	at	least	one	AE-AE	was	coded	as	1	and	AERs	that	did	not	were	coded	
as	0.	The	AS-AEs	included:	addiction,	dependence,	drug	abuse,	drug	dependence,	
drug	diversion,	intentional	misuse,	intentional	overdose,	multiple	drug	overdose,	
overdose,	substance	abuse,	and	substance	use.	MedDRA	terms	drug	abuser	and	
substance	abuser	were	not	included	as	AS-AEs	because	those	refer	to	the	social	
circumstances	surrounding	the	event.	Therefore,	information	may	be	provided	in	
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the	AER	that	the	individual	had	a	history	of	drug	misuse,	but	that	does	not	
necessarily	indicate	that	abuse	has	taken	place.	
	 Next,	loglinear	modeling	was	used	to	evaluate	the	association	between	the	co-
occurrence	of	an	AS-AE	and	each	AE	that	was	a	possible	indicator	of	abuse	(e.g.,	
ataxia,	substance	abuser)	in	AERs	for	gabapentin	and	pregabalin,	with	duloxetine	as	
the	referent	group.	Figure	4.1	depicts	an	exemplary	graphical	representation	of	
what	was	modeled,	particularly	for	AS-AE-feeling	drunk	co-reporting.	All	data	were	
assumed	to	have	come	from	a	Poisson	distribution.	Further,	AERs	that	co-indicated	
any	of	the	case	drugs	together	(e.g.,	AER	with	gabapentin	and	pregabalin;	AER	with	
pregabalin	and	duloxetine)	were	not	included	in	the	loglinear	analysis	in	an	attempt	
to	reduce	potential	conflation	of	effects.	SPSS	version	24	(IBM	Corp.,	Armonk,	New	
York)	was	used	to	conduct	the	analyses.	
Results	
	 From	2005-2015	there	were	6,685,853	unique	AE	reports	(AERs)	submitted	
to	the	FDA.	Of	those,	111,607	included	gabapentin,	80,251	included	duloxetine,	and	
111,012	included	pregabalin.	Overall,	the	number	of	reports	for	each	case	drug	
increased	annually	(Figure	4.2).	Interestingly,	AERs	for	gabapentin,	pregabalin,	and	
duloxetine	shared	many	of	same	most	frequently	reported	AEs	including	drug	
ineffectiveness,	pain,	nausea,	fatigue,	dizziness,	and	falls	(Table	4.2).			
	 Nearly	one-quarter	of	all	gabapentin	reports	involved	an	abuse-related	AE	
(23%;	Table	4.3).	That	percentage	was	slightly	higher	for	pregabalin	and	duloxetine	
(26	and	29%,	respectively).	Of	all	the	gabapentin-AR-AE	pairs,	dizziness	was	
reported	with	the	highest	frequency	(5%),	followed	by	falls	(5%),	and	somnolence	
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(3%).	Dizziness	and	somnolence	were	also	the	most	frequently	reported	AR-AEs	
reported	for	pregabalin	(7	and	5%,	respectively),	while	dizziness	(8%),	drug	
withdrawal	syndrome	(6%),	and	feeling	abnormal	(5%)	were	most	common	for	
duloxetine.	
	 When	examining	signal	measures	of	gabapentin,	only	four	pairs	did	not	
achieve	the	threshold	for	at	least	one	measure	(n=37)	and	nearly	half	of	the	
calculated	gabapentin-AR-AE	pairs	met	published	threshold	criteria	for	all	four	
measures	(n=16;	Table	4.4).	The	highest	gabapentin	signal	was	produced	by	the	PT	
substance	abuser	(ROR=14.7),	though	this	drug-AE	pair	had	a	frequency	of	only	2.	
The	other	largest	signals	for	gabapentin	were	produced	with	ataxia,	drug	tolerance,	
feeling	drunk,	multiple	drug	overdose,	substance-induced	psychosis,	and	abnormal	
thinking.	The	largest	signal	produced	for	pregabalin	was	with	the	PT,	feeling	drunk	
(PRR=11.6,	ROR=14.1,	IC=3.5,	EBGM=11.5),	followed	by	euphoric	mood,	
somnolence,	feeling	of	relaxation,	abnormal	thinking,	and	drug	tolerance.	The	
largest	signal	for	duloxetine	was	produced	with	drug	withdrawal	syndrome	
(PRR=13.8,	ROR=16.2,	IC=3.7,	EBGM=13.0),	with	abnormal	thinking	and	
dissociation	as	the	next	strongest	signals.	Signals	common	to	all	three	case	drugs	
included	confusional	state,	disorientation,	euphoric	mood,	feeling	drunk,	
hallucination,	visual	hallucination,	and	abnormal	thinking.	Drug-AR-AE	pair	signals	
unique	to	gabapentin	(compared	to	pregabalin	and	duloxetine)	were	with	the	AEs	
falls,	incoherence,	multiple	drug	overdose,	and	substance	induced	psychosis.	Drug-
AR-AE	signals	that	were	found	with	gabapentin	and	pregabalin,	but	not	duloxetine,	
were	ataxia,	drug	dependence,	drug	tolerance,	gait	disturbance,	and	somnolence.	
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There	were	no	drug-AR-AE	pairs	that	produced	signals	with	gabapentin	and	
duloxetine,	but	not	pregabalin.	Using	the	composite	AR-AE	variable,	pregabalin	and	
duloxetine	produced	signals	with	all	4	measures,	and	gabapentin	produced	signals	
with	all	measures	except	the	EBGM.	Using	the	composite	AS-AE	variable,	
gabapentin,	pregabalin,	and	duloxetine	all	produced	signals	with	the	ROR	and	IC,	but	
not	the	PRR	or	EBGM.	
	 Co-reporting	between	two	or	more	of	each	drug	accounted	for	between	7	and	
19%	of	all	AERs	for	each	drug.	When	the	number	of	reports	was	reduced	to	exclude	
overlap	between	gabapentin,	pregabalin,	and/or	duloxetine	the	number	of	unique	
reports	for	each	drug	was	97,235	for	gabapentin,	103,732	for	pregabalin,	and	
65,179	for	duloxetine.	AS-AEs	accounted	for	approximately	3%	of	each	drug’s	
reduced	number	of	AERs.	For	gabapentin,	somnolence,	drug	withdrawal	syndrome,	
and	falls	were	most	often	co-reported	with	an	AS-AE	(Table	4.5).	Somnolence	was	
also	the	most	often	co-reported	with	a	pregabalin	AS-AE,	while	drug	withdrawal	
syndrome	had	the	highest	co-occurrence	for	duloxetine.	
	 Based	on	results	from	the	loglinear	models,	compared	to	duloxetine,	
gabapentin	had	nearly	10	times	the	odds	of	a	co-report	of	drug	abuse	and	drug	
withdrawal	syndrome;	pregabalin	also	had	increased	odds	of	this	simultaneous	
report	compared	to	duloxetine,	but	not	as	high	as	gabapentin	(Table	4.6).	
Gabapentin	and	pregabalin	also	had	significantly	increased	odds	of	a	co-report	for	
an	AS-AE	with	auditory	hallucinations	(OR:	5.25	and	4.12,	respectively),	delusions	
(OR:	3.15	and	4.77,	respectively),	and	euphoric	mood	(OR:	2.69	and	2.24,	
respectively)	compared	to	the	negative	control.	Interestingly,	an	abuse-specific	
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event	and	ataxia	were	reported	together	with	significantly	increased	odds	for	
gabapentin	compared	to	duloxetine,	but	pregabalin	did	not	have	significantly	
increased	odds;	this	occurred	with	an	AS-AE-somnolence	co-report,	as	well.	
Discussion	
	 This	study	was	the	first	post-market	pharmacovigilance	study	to	examine	
gabapentin	reporting	in	the	FDA	Adverse	Event	Reporting	System	and	compare	
findings	to	a	negative	and	positive	control.	Though	gabapentin,	pregabalin,	and	
duloxetine	reports	all	produced	signals	for	any	abuse-related	and	abuse-specific	
adverse	events,	important	differences	appeared	when	evaluating	AE-ARs	
individually.	Specifically,	the	strongest	gabapentin-AER	associations	occurred	with	
ataxia,	drug	tolerance,	and	feeling	drunk,	all	three	of	which	were	among	the	highest	
pregabalin-AER	signals,	as	well.	This	is	not	surprising	given	that	gabapentin	and	
pregabalin	have	similar	mechanisms	of	action,	and	are	likely	to	produce	similar	
effects.		
	 Another	novel	aspect	of	the	current	study	is	that	we	evaluated	AERs	where	
drug	abuse	was	indicated	and	assessed	which	effects	were	most	often	co-reported	
with	abuse.	Drug	withdrawal	syndrome,	auditory	hallucinations,	delusions,	and	
euphoric	mood	were	more	often	endorsed	in	combination	with	drug	abuse	for	
gabapentin	or	pregabalin	compared	to	the	negative	control,	duloxetine.	While	it	is	
not	necessarily	remarkable	that	such	effects	have	been	reported	for	gabapentin	and	
pregabalin	(in	fact	several	of	these	AEs	are	listed	on	the	package	inserts),	what	is	
particularly	notable	is	that	they	were	reported	as	occurring	with	drug	abuse,	which	
gives	insight	into	the	psychoactive	effects	that	may	be	sought	through	misuse	of	
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these	drugs.	In	a	study	by	Schifano	and	colleagues	(2011),	data	were	accumulated	
from	online	anecdotes	of	recreational	misuse	of	gabapentinoids	and	the	effects	
achieved	echoed	those	identified	in	this	study.36	Though	pregabalin	has	been	
recognized	by	Drug	Enforcement	Agency	in	the	United	States16	and	the	European	
Monitoring	Centre	for	Drugs	and	Drug	Addiction	(EMCDDA)-Europol94	as	having	
abuse	liability,	gabapentin	is	still	assumed	to	have	no	abuse	potential.	However,	the	
similarities	between	gabapentin	and	pregabalin	of	reported	effects	in	combination	
with	drug	abuse	underscore	the	necessity	of	revisiting	evaluation	of	the	abuse	
liability	of	gabapentin.	
	 Interestingly,	drug	abuse	was	co-reported	with	somnolence	and	ataxia	with	
significantly	higher	odds	for	gabapentin	compared	to	duloxetine,	but	this	effect	was	
not	observed	with	pregabalin.	Ataxia	and	somnolence	are	common	experiences	of	
alcohol	intoxication;126,127	gabapentin	has	produced	similar	effects	in	the	human	
laboratory59	and,	in	a	study	by	Peterson	(2009),	gabapentin	was	identified	in	137	
driving	impairment	cases	in	Washington.37	Studies	to	examine	how	gabapentin	
misuse	may	impact	psychomotor	effects	are	warranted.	
	 Gabapentin	abuse	signals	were	identified	using	national	AE	reporting	data	
from	the	United	States,	however,	this	is	not	just	an	American	phenomenon.	As	
mentioned	earlier,	a	review	by	Smith	et	al.	(2016)	noted	that	gabapentin	misuse	
reports	have	also	come	from	the	United	Kingdom,	Germany,	Finland,	India,	South	
Africa,	and	France.	Further,	in	a	recent	paper	by	Chiappini	and	Schifano	(2016)	
similar	methodologies	as	those	conducted	in	the	present	study	were	used	to	
examine	gabapentinoid	misuse	in	the	European	Medicines	Agency	Suspected	
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Adverse	Drug	Reactions	database.128	The	authors	identified	nearly	5%	of	
misuse/abuse/dependence	spontaneous	AE	reports	were	associated	with	
gabapentin.128	Evaluation	of	the	Canadian	Vigilance	Adverse	Drug	Reaction	Online	
Database	also	demonstrated	gabapentin	misuse.129		
The	current	study	has	several	limitations.	FAERS	has	a	low	spontaneous	
reporting	rate,	containing	an	average	of	only	6%	of	all	occurring	drug-associated	
AEs.130	As	a	result,	causality,	incidence,	and	prevalence	cannot	be	determined.131,132	
However,	the	abuse	signals	detected	herein	provide	a	critical	indication	that	further	
examination	is	required,133	especially	in	the	context	of	a	growing	number	of	case	
reports	of	gabapentin	misuse.	Also,	many	external	factors	affect	FAERS	reporting	
such	as	the	“notoriety	effect,”134	which	is	the	uptick	in	reporting	resulting	from	a	
safety	alert,	or	the	“ripple	effect”	where	reporting	is	accelerated	following	notoriety	
of	a	drug	in	the	same	class,134	among	others.135-137	By	cumulating	data	over	the	11-
year	study	period,	we	at	least	partially	mitigated	the	impact	of	any	fluctuations	
present	in	the	data.	It	is	important	to	note	that	some	of	the	signals	detected	could	be	
confounded	by	the	population	for	whom	they	are	being	prescribed	(e.g.,	
gabapentinoids	prescribed	off	label	for	mood	disorders)	as	well	as	due	to	
interactions	with	concomitant	medications.	However,	the	purpose	of	this	study	was	
not	to	assess	cause-and-effect,	rather	to	attempt	to	corroborate	described	effects	in	
case	reports	and	to	provide	hypotheses	for	future	controlled	clinical	studies.	
This	study	identified	abuse-related	signals	for	gabapentin,	as	well	as	
elucidated	several	CNS	effects	that	may	be	associated	with	its	abuse.	Future	studies	
are	necessary	to	determine	whether	these	are	a	direct	result	of	gabapentin	and	
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investment	in	larger,	controlled	pharmacological	studies	is	warranted.	Prescribers	
should	be	aware	of	gabapentin’s	abuse	liability	and	effects	that	may	accompany	its	
misuse.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	63	
Table	4.1.	2x2	contingency	table	used	for	pharmacovigilance	measures.	
	
With	AE	of	interest	
Without	AE	of	
interest	 Total	
Drug	of	interest	 n11	 n12	 n1+	
Without	drug	of	
interest	 n21	 n22	 n2+	
Total	 n+1	 n+2	 n	
n1+:	marginal	frequency	of	the	drug	of	interest;	n+1:	marginal	frequency	of	the	AE	of	
interest;	n:	total	sample	size.
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Figure	4.1.	Tree	diagram	of	an	example	of	the	loglinear	model.		
	
GBP:	gabapentin;	PRG:	pregabalin;	Dulox:	duloxetine;	AS-AE:	abuse-specific-adverse	
event;	+:	present;	-:	absent.
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Figure	4.2.	Adverse	reporting	trends	by	quarter,	2005-2015	
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Table	4.2.	Highest	frequency	of	adverse	events	by	drug,	2005-2015	
Gabapentin	(n)	 Pregabalin	(n)	 Duloxetine	(n)	
Drug	ineffective	(10668)	 Pain	(11568)	 Nausea	(7945)	
Pain	(8370)	 Drug	ineffective	(10199)	 Dizziness	(6307)	
Nausea	(7348)	 Dizziness	(7478)	 Headache	(5516)	
Fatigue	(6610)	 Weight	increased	(6591)	 Pain	(5464)	
Dizziness	(5936)	 Somnolence	(5744)	 Fatigue	(5300)	
Headache	(5585)	 Nausea	(5119)	 Drug	ineffective	(5291)	
Fall	(5285)	 Malaise	(4738)	 Drug	withdrawal	
syndrome	(4870)	
Dyspnea	(5173)	 Pain	in	extremity	(4698)	 Depression	(4577)	
Diarrhea	(5130)	 Fatigue	(4687)	 Insomnia	(4481)	
Depression	(4899)	 Feeling	abnormal	(4445)	 Feeling	abnormal	(4106)	
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Table	4.3.	Frequency	of	abuse-related	adverse	event	reports	by	case	drug,	2005-
2015	
Preferred	term	
Gabapentin	
(n=111607)	
n(%)	
Pregabalin	
(n=111012)	
n(%)	
Duloxetine		
(n=80251)	
n(%)	
Addiction	 0	(0)	 0	(0)	 0	(0)	
Aggression	 667	(.60)	 596	(.54)	 746	(.93)	
Ataxia	 298	(.27)	 267	(.24)	 117	(.15)	
Confusional	state	 2902	(2.60)	 2733	(2.46)	 2057	(2.56)	
Delirium	 451	(.40)	 408	(.37)	 300	(.37)	
Delusion	 196	(.18)	 125	(.11)	 180	(.22)	
Dependence	 97	(.09)	 76	(.07)	 51	(.06)	
Disorientation	 840	(.75)	 824	(.74)	 625	(.78)	
Dissociation	 58	(.05)	 97	(.09)	 109	(.14)	
Dizziness	 5921	(5.31)	 7508	(6.76)	 6270	(7.81)	
Drug	abuse	 597	(.53)	 766	(.69)	 294	(.37)	
Drug	abuser	 134	(.12)	 33	(.03)	 33	(.04)	
Drug	addict	 0	(0)	 0	(0)	 0	(0)	
Drug	dependence	 614	(.55)	 704	(.63)	 248	(.31)	
Drug	diversion	 11	(.01)	 11	(.01)	 30	(.04)	
Drug	tolerance	 105	(.09)	 111	(.10)	 47	(.06)	
Drug	withdrawal	
syndrome	
1059	(.95)	 1618	(1.46)	 4857	(6.05)	
Elevated	mood	 6	(.01)	 20	(.02)	 20	(.02)	
Euphoric	mood	 190	(.17)	 597	(.54)	 159	(.20)	
Fall	 5290	(4.74)	 4381	(3.95)	 3212	(4.00)	
Feeling	abnormal	 3064	(2.75)	 4425	(3.99)	 4103	(5.11)	
Feeling	drunk	 242	(.22)	 670	(.60)	 177	(.22)	
Feeling	of	relaxation	 11	(.01)	 28	(.03)	 18	(.02)	
Gait	disturbance	 3090	(2.77)	 3443	(3.10)	 1667	(2.08)	
Hallucination	 1082	(.97)	 1061	(.96)	 904	(1.13)	
Hallucination,	
auditory	
166	(.15)	 140	(.13)	 191	(.24)	
Hallucination,	visual	 295	(.26)	 290	(.26)	 208	(.26)	
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Hallucination,	mixed	 48	(.04)	 57	(.05)	 48	(.06)	
Incoherent	 156	(.14)	 128	(.12)	 92	(.11)	
Intentional	(drug)	
misuse	
651	(.58)	 726	(.65)	 513	(.64)	
Intentional	overdose	 535	(.48)	 373	(.34)	 409	(.51)	
Intoxication	 0	(0)	 0	(0)	 0	(0)	
Mood	altered	 312	(.28)	 386	(.35)	 382	(.48)	
Multiple	drug	
overdose	
275	(.25)	 47	(.04)	 53	(.07)	
Off	label	use	 2325	(2.08)	 2118	(1.91)	 3058	(3.81)	
Overdose	 1500	(1.34)	 1053	(.95)	 865	(1.08)	
Prescription	drug	use	
without	a	
prescription	
0	(0)	 0	(0)	 0	(0)	
Psychosis	 0	(0)	 0	(0)	 0	(0)	
Acute	psychosis	 13	(.01)	 1	(<.01)	 7	(.01)	
Rebound	psychosis	 1	(<.01)	 0	(0)	 0	(0)	
Transient	psychosis	 0	(0)	 0	(0)	 0	(0)	
Somnolence	 3667	(3.29)	 5722	(5.15)	 2585	(3.22)	
Substance	abuse	 79	(.07)	 24	(.02)	 26	(.03)	
Substance	abuser	 2	(<.01)	 0	(0)	 0	(0)	
Substance	induced	
psychosis	
23	(.02)	 10	(.01)	 7	(.01)	
Substance	use	 7	(.01)	 5	(<.01)	 1	(<.01)	
Thinking	abnormal	 676	(.61)	 637	(.57)	 588	(.73)	
Tolerance	increased	 0	(0)	 0	(0)	 0	(0)	
Any	AR-AE	 26049	(23.34)	 29159	(26.27)	 23320	(29.06)	
	AR-AE:	abuse-related	adverse	event.	
Note:	Percentages	are	out	of	the	total	number	of	reports	for	each	case	drug.	
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Table	4.4.	Signal	scores	for	gabapentin-,	pregabalin-,	and	duloxetine-associated	
abuse-related	adverse	events.	
Preferr
ed	term	
Gabapentin	 Pregabalin	 Duloxetine	
PRR		
(χ2)	
ROR		
(95%	
CI)	
IC		
(IC0
25)	
EB
GM	
(EB
05)	
PRR		
(χ2)	
RO
R		
(95
%	
CI)	
IC		
(IC0
25)	
EBG
M	
(EB
05)	
PRR		
(χ2)	
RO
R		
(95
%	
CI)	
IC		
(IC0
25)	
EBG
M	
(EB
05)	
Aggress
ion	
1.55	
(131.2
9)	
1.56	
(1.49,
1.64)	
0.6
3	
(0.3
6)	
1.5
5	
(1.4
5)	
1.38	
(63.52
)	
1.3
9		
(1.3
1,	
1.4
7)	
0.4
6		
(0.2
4)	
1.38	
(1.2
9)	
2.39	
(606.
42)	
2.4
3		
(2.3
6,	
2.5
1)	
1.2
5	
(0.7
9)	
2.3
8	
(2.2
3)	
Ataxia	 3.48	
(535.
24)	
3.64		
(3.52,	
3.75)	
1.8
0	
(3.9
6)	
3.4
8	
(3.
14)	
3.12	
(389.
30)	
3.2
3		
(3.1
1,	
3.3
6)	
1.6
4		
(1.0
1)	
3.1
1	
(2.7
9)	
1.88	
(48.73
)	
1.9
0		
(1.7
2,	
2.0
8)	
0.9
1	
(0.4
4)	
1.88	
(1.5
9)	
Confusi
onal	
state	
2.73	
(3143
.98)	
2.81		
(2.77,	
2.85)	
1.4
2		
(0.9
5)	
2.6
8	
(2.
60)	
2.56	
(2579
.04)	
2.6
3		
(2.5
9,	
2.6
7)	
1.3
3		
(0.8
9)	
2.5
2	
(2.4
4)	
2.66	
(2099
.99)	
2.7
1		
(2.6
7,	
2.7
6)	
1.3
9	
(0.9
2)	
2.6
2	
(2.5
2)	
Deliriu
m	
2.08	
(254.
89)	
2.11		
(2.02,	
2.21)	
1.0
5		
(0.6
3)	
2.0
7	
(DN
E)	
1.88	
(168.8
4)	
1.9
0		
(1.8
0,	
2.0
0)	
0.9
0		
(0.5
3)	
1.87	
(1.7
2)	
1.90	
(129.0
5)	
1.9
2		
(1.8
1,	
2.0
4)	
0.9
2	
(0.5
3)	
1.90	
(1.7
1)	
Delusio
n	
1.94	
(90.18
)	
1.97		
(1.83,	
2.11)	
0.9
5		
(0.5
2)	
1.9
4	
(1.7
0)	
1.23		
(5.58)	
1.2
4		
(1.0
6,	
1.4
1)	
0.3
0		
(0.0
3)	
1.23	
(1.0
6)	
2.45	
(155.
92)	
2.4
9		
(2.3
5,	
2.6
4)	
1.2
9	
(0.7
4)	
2.4
5	
(2.1
4)	
Depend
ence	
1.81	
(35.83
)	
1.84		
(1.63,	
2.04)	
0.8
6		
(0.3
9)	
1.8
1	
(1.5
1)	
1.42		
(9.48)	
1.4
3		
(1.2
0,	
1.6
5)	
0.5
0		
(0.1
1)	
1.42	
(1.1
6)	
1.31		
(3.80)	
1.3
2		
(1.0
4,	
1.5
9)	
0.39	
(0.0
0)	
1.31	
(1.0
2)	
Disorie
ntatio
n	
2.55	
(800.
29)	
2.62		
(2.55,	
2.69)	
1.3
5		
(0.8
7)	
2.5
4	
(2.
39)	
2.50	
(748.
40)	
2.5
6		
(2.4
9,	
2.6
3)	
1.3
2		
(0.8
4)	
2.4
9	
(2.3
4)	
2.61	
(625.
58)	
2.6
7		
(2.5
9,	
2.7
5)	
1.3
8	
(0.8
8)	
2.6
0	
(2.4
3)	
Dissoci
ation	
2.00	
(29.5
2.04		
(1.77,	
1.0
0		
2.0
0	
3.34	
(161.
3.4
8		
1.7
4		
3.3
4	
5.18	
(371.
5.4
6		
2.3
7	
5.1
7	
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1)	 2.30)	 (0.4
2)	
(1.5
6)	
83)	 (3.2
8,	
3.6
9)	
(0.9
9)	
(2.7
5)	
61)	 (5.2
7,	
5.6
5)	
(1.4
3)	
(5.6
0)	
Dizzine
ss	
1.91	
(2469.
29)	
1.94		
(1.91,	
1.97)	
0.9
0		
(0.6
0)	
1.8
6	
(1.8
2)	
2.45	
(6138
.12)	
2.5
1		
(2.4
9,	
2.5
4)	
1.2
4		
(0.8
4)	
2.3
6	
(2.3
1)	
2.86	
(7062
.65)	
2.9
2		
(2.8
9,	
2.9
5)	
1.4
4	
(0.9
7)	
2.71	
(DN
E)	
Drug	
abuse	
1.54	
(113.6
7)	
1.55		
(1.47,	
1.63)	
0.6
2		
(0.3
5)	
1.5
4	
(1.4
3)	
1.97	
(371.6
6)	
2.0
1		
(1.9
3,	
2.0
8)	
0.9
8		
(0.6
1)	
1.97	
(1.8
5)	
1.04		
(0.47)	
1.0
4		
(0.9
3,	
1.1
6)	
0.06	
(0.0
0)	
1.04	
(0.9
4)	
Drug	
abuse
r	
1.87	
(54.76
)	
1.89		
(1.72,	
2.07)	
0.9
0		
(0.4
4)	
1.8
7	
(1.6
0)	
0.46	
(21.44
)	
0.4
5		
(0.1
1,	
0.8
0)	
-
1.1
2		
(0.0
1)	
0.46	
(0.3
5)	
0.63		
(7.15)	
0.6
3		
(0.2
9,	
0.9
7)	
-
0.66	
(0.0
0)	
0.63	
(DN
E)	
Drug	
depe
ndenc
e	
2.56	
(588.
20)	
2.63		
(2.54,	
2.71)	
1.3
5		
(0.8
5)	
2.5
5	
(2.
37)	
2.93	
(903.
80)	
3.0
3		
(2.9
5,	
3.1
0)	
1.5
4		
(1.0
0)	
2.9
2	
(2.7
3)	
1.42	
(30.76
)	
1.4
2		
(1.3
0,	
1.5
5)	
0.5
0	
(0.2
2)	
1.42	
(1.2
7)	
Drug	
diver
sion	
0.52		
(4.84)	
0.52		
(-0.07,	
1.11)	
-
0.93	
(0.0
0)	
0.5
2	
(0.3
3)	
0.52		
(4.87)	
0.5
2		
(-
0.0
7,	
1.1
1)	
-
0.93		
(0.0
0)	
0.52	
(0.3
3)	
1.97	
(14.42
)	
1.9
9		
(1.6
3,	
2.3
5)	
0.9
8	
(0.2
8)	
1.97	
(1.3
8)	
Drug	
tolera
nce	
4.07	
(247.
19)	
4.30		
(4.10,	
4.49)	
2.0
2		
(1.1
9)	
4.0
7	
(3.
34)	
4.30	
(285.
44)	
4.5
5		
(4.3
6,	
4.7
5)	
2.1
0		
(1.2
6)	
4.3
0	
(3.5
6)	
2.51	
(43.0
9)	
2.5
5		
(2.2
6,	
2.8
5)	
1.3
3	
(0.6
0)	
2.51	
(DN
E)	
Drug	
withd
rawal	
syndr
ome	
2.07	
(590.
03)	
2.11		
(2.05,	
2.17)	
1.0
4		
(0.6
6)	
2.0
6	
(1.9
5)	
3.17	
(2415
.25)	
3.2
9		
(3.2
4,	
3.3
5)	
1.6
5		
(1.1
0)	
3.1
4	
(3.0
1)	
13.77	
(5472
5.12)	
16.
16	
(16.
13,	
16.
19)	
3.7
0	
(2.5
4)	
13.
00	
(12.
92)	
Elevate
d	
mood	
0.76	
(0.48)	
0.75		
(-0.05,	
1.56)	
-
0.41	
(0.0
0)	
0.7
6	
(0.3
9)	
2.51	
(18.5
4)	
2.5
8		
(2.1
3,	
3.0
3)	
1.3
3		
(0.4
0)	
2.51	
(1.5
7)	
3.46	
(35.4
9)	
3.5
7		
(3.1
3,	
4.0
2)	
1.7
9	
(0.7
1)	
3.4
6	
(2.0
9)	
Euphori 2.45	 2.51		 1.2 2.4 7.72	 8.7 2.9 7.6 2.83	 2.8 1.5 2.8
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c	
mood	
(165.
91)	
(2.37,	
2.66)	
9	
(0.7
5)	
5	
(2.
15)	
(3534
.35)	
1		
(8.6
3,	
8.8
0)	
4		
(1.9
6)	
9	
(7.6
4)	
(189.
41)	
9		
(2.7
3,	
3.0
5)	
0	
(0.8
8)	
2	
(2.4
4)	
Fall	 2.50	
(4626
.41)	
2.57		
(2.54,	
2.60)	
1.2
8		
(0.8
6)	
2.4
3	
(2.
38)	
2.05	
(2310
.74)	
2.0
9		
(2.0
6,	
2.1
2)	
1.0
1		
(0.6
7)	
2.01	
(1.9
6)	
2.07	
(1738
.93)	
2.1
0		
(2.0
7,	
2.1
4)	
1.0
2	
(0.6
8)	
2.03	
(DN
E)	
Feeling	
abnor
mal	
2.03	
(1587
.00)	
2.07		
(2.03,	
2.10)	
1.0
0		
(0.6
6)	
2.0
0	
(1.9
4)	
2.97	
(5635
.13)	
3.0
7		
(3.0
4,	
3.1
0)	
1.5
3		
(1.0
3)	
2.8
9	
(2.8
2)	
3.84	
(8264
.66)	
3.9
7		
(3.9
4,	
4.0
0)	
1.8
8	
(1.2
8)	
3.6
9	
(3.6
0)	
Feeling	
drunk	
4.17	
(592.
69)	
4.41		
(4.28,	
4.54)	
2.0
6		
(1.3
0)	
4.1
7	
(3.
67)	
11.58	
(6550
.01)	
14.
11	
(14.
02,	
14.
19)	
3.5
3		
(2.3
7)	
11.
52	
(11.
33)	
4.20	
(436.
17)	
4.3
7		
(4.2
2,	
4.5
2)	
2.0
7	
(1.2
8)	
4.1
9	
(3.6
3)	
Feeling	
of	
relax
ation	
1.80		
(3.98)	
1.83		
(1.23,	
2.43)	
0.85		
(0.0
0)	
1.8
0	
(0.9
8)	
4.58	
(79.6
0)	
4.8
7		
(4.4
9,	
5.2
6)	
2.1
9		
(1.0
7)	
4.5
8	
(3.0
9)	
4.06	
(41.9
4)	
4.2
1		
(3.7
4,	
4.6
9)	
2.0
2	
(0.8
1)	
4.0
5	
(2.3
3)	
Gait	
distur
bance	
2.54	
(2851
.64)	
2.61		
(2.57,	
2.64)	
1.3
2		
(0.8
8)	
2.5
0	
(2.
42)	
2.83	
(4030
.27)	
2.9
2		
(2.8
9,	
2.9
6)	
1.4
7		
(0.9
9)	
2.7
8	
(2.7
0)	
1.87	
(671.1
5)	
1.8
9		
(1.8
4,	
1.9
4)	
0.8
9	
(0.5
7)	
1.85	
(1.7
8)	
Halluci
natio
n	
2.44	
(928.
02)	
2.50		
(2.44,	
2.56)	
1.2
8		
(0.8
3)	
2.4
3	
(2.
30)	
2.39	
(864.
88)	
2.4
5		
(2.3
9,	
2.5
1)	
1.2
5		
(0.8
1)	
2.3
8	
(2.2
6)	
2.81	
(1056
.83)	
2.8
8		
(2.8
1,	
2.9
4)	
1.4
8	
(0.9
6)	
2.7
9	
(2.6
4)	
Halluci
natio
n,	
audit
ory	
1.52	
(29.76
)	
1.53		
(1.38,	
1.69)	
0.6
0		
(0.2
6)	
1.5
2	
(1.3
2)	
1.28		
(8.59)	
1.2
8		
(1.1
2,	
1.4
5)	
0.3
5		
(0.0
7)	
1.28	
(1.1
0)	
2.41	
(158.
37)	
2.4
5		
(2.3
0,	
2.5
9)	
1.2
6	
(0.7
3)	
2.4
0	
(2.1
1)	
Halluci
natio
n,	
visual	
2.38	
(239.
24)	
2.44		
(2.32,	
2.55)	
1.2
5		
(0.7
5)	
2.3
8	
(2.
14)	
2.34	
(224.
67)	
2.3
9		
(2.2
7,	
2.5
1)	
1.2
2		
(0.7
3)	
2.3
3	
(2.1
0)	
2.31	
(155.
79)	
2.3
5		
(2.2
1,	
2.4
8)	
1.2
0	
(0.7
0)	
2.3
1	
(2.0
3)	
Halluci 1.98	 2.01		 0.9 1.9 2.35	 2.4 1.2 2.35	 2.73	 2.7 1.4 2.7
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natio
n,	
mixe
d	
(23.70
)	
(1.73,	
2.30)	
9		
(0.3
7)	
8	
(1.5
1)	
(44.8
9)	
0		
(2.1
4,	
2.6
7)	
3		
(0.5
7)	
(1.8
2)	
(53.0
9)	
9		
(2.5
0,	
3.0
7)	
5	
(0.6
9)	
3	
(2.0
4)	
Incoher
ent	
2.59	
(154.
86)	
2.66		
(2.50,	
2.82)	
1.3
7		
(0.7
8)	
2.5
9	
(2.
23)	
2.12	
(77.2
4)	
2.1
6		
(1.9
9,	
2.3
4)	
1.0
9		
(0.5
7)	
2.12	
(1.8
1)	
2.10	
(53.8
2)	
2.1
3		
(1.9
2,	
2.3
4)	
1.0
7	
(0.5
2)	
2.10	
(1.7
3)	
Intentio
nal	
(drug
)	
misus
e	
1.69	
(185.1
1)	
1.71		
(1.63,	
1.79)	
0.7
5		
(0.4
5)	
1.6
9	
(1.5
8)	
1.88	
(303.5
0)	
1.9
1		
(1.8
4,	
1.9
9)	
0.9
1		
(0.5
6)	
1.88	
(1.7
6)	
1.83	
(195.3
4)	
1.8
5		
(1.7
6,	
1.9
4)	
0.8
7	
(0.5
1)	
1.83	
(1.6
9)	
Intentio
nal	
overd
ose	
1.79	
(188.2
5)	
1.81		
(1.73,	
1.90)	
0.8
4		
(0.4
9)	
1.7
8	
(1.6
6)	
1.24	
(18.02
)	
1.2
5		
(1.1
5,	
1.3
5)	
0.3
1		
(0.1
1)	
1.24	
(1.1
4)	
1.88	
(170.3
7)	
1.9
0		
(1.8
0,	
2.0
0)	
0.9
1	
(0.5
3)	
1.88	
(DN
E)	
Mood	
altere
d	
1.70	
(91.52
)	
1.72		
(1.61,	
1.83)	
0.7
7		
(0.4
2)	
1.7
0	
(1.5
4)	
2.10	
(226.
50)	
2.1
4		
(2.0
4,	
2.2
5)	
1.0
7		
(0.6
4)	
2.10	
(1.9
2)	
2.87	
(469.
88)	
2.9
4		
(2.8
4,	
3.0
4)	
1.5
2	
(0.9
5)	
2.8
6	
(2.6
1)	
Multipl
e	
drug	
overd
ose	
4.07	
(646.
61)	
4.30		
(4.17,	
4.42)	
2.0
2		
(1.2
8)	
4.0
6	
(3.
62)	
0.69		
(6.47)	
0.6
9		
(0.4
0,	
0.9
8)	
-
0.53		
(0.0
0)	
0.69	
(0.5
4)	
1.08		
(0.30)	
1.0
8		
(0.8
1,	
1.3
5)	
0.11	
(0.0
0)	
1.08	
(0.8
5)	
Off	
label	
use	
1.61	
(535.0
2)	
1.63		
(1.59,	
1.67)	
0.6
8		
(0.4
3)	
1.6
0	
(1.5
4)	
1.46	
(308.2
7)	
1.4
7		
(1.4
3,	
1.5
2)	
0.5
4		
(0.3
3)	
1.45	
(1.4
0)	
2.97	
(3880
.43)	
3.0
4		
(3.0
0,	
3.0
7)	
1.5
3	
(1.0
3)	
2.8
9	
(2.8
0)	
Overdo
se	
1.65	
(381.6
5)	
1.66		
(1.61,	
1.72)	
0.7
1		
(0.4
4)	
1.6
4	
(1.5
7)	
1.15	
(20.57
)	
1.1
5		
(1.0
9,	
1.2
1)	
0.2
0		
(0.0
8)	
1.15	
(1.0
9)	
1.30	
(60.96
)	
1.3
1		
(1.2
4,	
1.3
8)	
0.3
8	
(0.1
9)	
1.30	
(1.2
3)	
Acute	
psych
osis	
0.70		
(1.70)	
0.70		
(0.15,	
1.24)	
-
0.51	
(0.0
0)	
0.7
0	
(0.4
5)	
--	 --	 -
4.2
2		
(0.0
1)	
0.05	
(0.0
3)	
0.52		
(3.16)	
0.5
2		
(-
0.2
3,	
1.2
6)	
-
0.95	
(0.0
0)	
0.52	
(0.2
9)	
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Reboun
d	
psych
osis	
--	 --	 1.90		
(0.0
0)	
3.7
4	
(0.4
1)	
--	 --	 --	 --	 --	 --	 --	 --	
Somnol
ence	
3.04	
(4937
.41)	
3.15		
(3.11,	
3.18)	
1.5
7		
(1.0
6)	
2.9
7	
(2.
89)	
4.83	
(1676
1.46)	
5.1
5		
(5.1
2,	
5.1
8)	
2.2
1		
(1.5
1)	
4.6
3	
(4.5
9)	
2.95	
(3257
.42)	
3.0
2		
(2.9
8,	
3.0
6)	
1.5
3	
(1.0
2)	
2.88	
(DN
E)	
Substan
ce	
abuse	
1.50	
(13.42
)	
1.51		
(1.29,	
1.74)	
0.5
9		
(0.1
7)	
1.5
0	
(1.2
3)	
0.46	
(15.92
)	
0.4
5		
(0.0
5,	
0.8
5)	
-
1.1
4		
(0.0
1)	
0.46	
(DN
E)	
0.68		
(3.98)	
0.6
8		
(0.2
9,	
1.0
6)	
-
0.56	
(0.0
0)	
0.68	
(0.4
9)	
Substan
ce	
abuse
r	
--	 14.73	
(13.1
8,	
16.28
)	
3.58		
(0.0
0)	
11.
98	
(0.9
9)	
--	 --	 --	 --	 --	 --	 --	 --	
Substan
ce	
induc
ed	
psych
osis	
4.02	
(53.0
0)	
4.23		
(3.81,	
4.66)	
2.0
1		
(0.8
8)	
4.0
2	
(2.
53)	
1.74		
(3.23)	
1.7
7		
(1.1
4,	
2.4
0)	
0.80		
(0.0
0)	
1.74	
(0.9
3)	
1.68		
(1.96)	
1.7
0		
(0.9
5,	
2.4
5)	
0.75	
(0.0
0)	
1.68	
(DN
E)	
Substan
ce	
use	
2.81	
(8.33)	
2.90		
(2.15,	
3.66)	
1.4
9		
(0.0
8)	
2.8
1	
(1.1
6)	
2.01	
(2.57)	
2.0
4		
(1.1
5,	
2.9
3)	
1.01		
(0.0
0)	
2.01	
(0.7
8)	
--	 --	 -
0.85	
(0.0
0)	
--	
Thinkin
g	
abnor
mal	
4.48	
(1843
.94)	
4.75		
(4.68,	
4.83)	
2.1
6		
(1.4
2)	
4.4
5	
(4.
35)	
4.21	
(1576
.28)	
4.4
5		
(4.3
7,	
4.5
3)	
2.0
7		
(1.3
5)	
4.1
9	
(3.9
0)	
5.36	
(2097
.80)	
5.6
7		
(5.5
8,	
5.7
5)	
2.4
1	
(1.5
9)	
5.3
3	
(5.2
1)	
Any	AR-
AE	
2.15	
(1254
7.84)	
2.19	
(2.18,	
2.21)	
0.9
1	
(0.6
2)	
1.8
8	
(1.8
6)	
2.50	
(1966
8.62)	
2.5
5	
(2.5
4,	
2.5
7)	
1.0
7	
(0.7
4)	
2.1
1	
(2.0
9)	
2.86	
(2027
1.95)	
2.9
1	
(2.8
9,	
2.9
2)	
1.2
2	
(0.8
3)	
2.3
2	
(2.3
0)	
Any	AS-
AE	
1.76	
(1256.
07)	
1.78	
(1.75,	
1.81)	
0.7
9	
(0.5
2)	
1.7
3	
(1.6
8)	
1.50	
(546.5
2)	
1.5
1	
(1.4
7,	
1.5
4)	
0.5
7	
(0.3
6)	
1.48	
(1.4
4)	
1.40	
(263.1
5)	
1.4
1	
(1.3
7,	
1.4
5)	
0.4
8	
(0.2
9)	
1.39	
(DN
E)	
PRR:	proportional	reporting	ratio;	χ2:	chi-squared	critical	value;	ROR:	reporting	
odds	ratio;	95%	CI:	95%	confidence	interval;	IC:	information	component;	IC025:	
lower	limit	of	the	two-sided	95%	credibility	interval;	EBGM:	empirical	Bayesian	
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geometric	mean;	EB05:	lower	one-sided	95%	credible	interval	for	the	EBGM;	DNE:	
does	not	exist;	AR-AE:	abuse-related	adverse	event;	AS-AE:	abuse-specific	adverse	
event.	
--	indicates	the	frequency	was	too	low	to	calculate	the	signal	measure	
Boldface	indicates	published	signal	threshold	criteria	met.	
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Table	4.5.	Frequency	of	co-reporting	of	an	abuse-specific	adverse	event	by	case	drug	
and	non-specific-abuse-related	adverse	event,	2005-2015	
Preferred	term	
Gabapentin		
(n=3936)	
n(%)	
Pregabalin		
(n=3375)	
n(%)	
Duloxetine		
(n=2303)	
n(%)	
Aggression	 90	(2.3)	 89	(2.6)	 40	(1.7)	
Ataxia	 49	(1.2)	 17	(0.5)	 4	(0.2)	
Confusional	state	 186	(4.7)	 119	(3.5)	 88	(3.8)	
Delirium	 57	(1.4)	 25	(0.7)	 25	(1.1)	
Delusion	 31	(0.8)	 24	(0.7)	 7	(0.3)	
Disorientation	 45	(1.1)	 41	(1.2)	 20	(0.9)	
Dissociation	 1	(<0.1)	 1	(<0.1)	 3	(0.1)	
Dizziness	 175	(4.4)	 158	(4.7)	 135	(5.9)	
Drug	abuser	 83	(2.1)	 18	(0.5)	 8	(0.3)	
Drug	tolerance	 46	(1.2)	 33	(1.0)	 7	(0.3)	
Drug	withdrawal	
syndrome	
247	(6.3)	 165	(4.9)	 155	(6.7)	
Elevated	mood	 0	(0)	 4	(0.1)	 1	(<0.1)	
Euphoric	mood	 44	(1.1)	 95	(2.8)	 9	(0.4)	
Fall	 203	(5.2)	 142	(4.2)	 74	(3.2)	
Feeling	abnormal	 107	(2.7)	 160	(4.7)	 106	(4.6)	
Feeling	drunk	 7	(0.2)	 23	(0.7)	 3	(0.1)	
Feeling	of	relaxation	 2	(0.1)	 6	(0.2)	 0	(0)	
Gait	disturbance	 86	(2.2)	 92	(2.7)	 45	(2.0)	
Hallucination	 85	(2.2)	 58	(1.7)	 39	(1.7)	
Hallucination,	
auditory	
24	(0.6)	 16	(0.5)	 4	(0.2)	
Hallucination,	visual	 20	(0.5)	 15	(0.4)	 8	(0.3)	
Hallucination,	mixed	 3	(0.1)	 12	(0.4)	 1	(<0.1)	
Incoherent	 17	(0.4)	 6	(0.2)	 6	(0.3)	
Mood	altered	 18	(0.5)	 19	(0.6)	 17	(0.7)	
Off	label	use	 79	(2.0)	 104	(3.1)	 109	(4.7)	
Acute	psychosis	 0	(0)	 0	(0)	 1	(<0.1)	
Rebound	psychosis	 0	(0)	 0	(0)	 0	(0)	
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Somnolence	 266	(6.8)	 278	(8.2)	 102	(4.4)	
Substance	abuser	 1	(<0.1)	 0	(0)	 0	(0)	
Substance	induced	
psychosis	
0	(0)	 1	(<0.1)	 0	(0)	
Thinking	abnormal	 45	(1.1)	 23	(0.7)	 25	(1.1)	
AR-AE:	abuse-related	adverse	event;	AS-AE:	abuse-specific	adverse	event.	
Note:	Frequencies	and	percentages	exclude	any	cases	where	case	drugs	were	co-
reported.	
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Table	4.6.	Loglinear	odds	ratio	estimates	for	the	interaction	between	a	report	of	an	
abuse-specific	adverse	event	and	a	possible	indicator	of	abuse	AE	by	drug.	
Interaction	
Gabapentin	
OR	(95%	CI)	
Pregabalin	
OR	(95%	CI)	
Duloxetine	
	
AS-AE*Aggression	 2.35	(1.58,	3.48)	 2.83	(1.91,	4.20)	 REF	
AS-AE*Ataxia	 3.04	(1.11,	8.28)	 1.18	(.40,	3.45)	 REF	
AS-AE*Confusional	
state	
1.14	(.87,	1.49)	 .80	(.60,	1.07)	 REF	
AS-AE*Delirium	 1.08	(.66,	1.79)	 .54	(.31,	.97)	 REF	
AS-AE*Delusion	 3.15	(1.37,	7.22)	 4.77	(2.02,	
11.27)	
REF	
AS-AE*Disorientation	 1.30	(.76,	2.22)	 1.32	(.73,	2.18)	 REF	
AS-AE*Dissociation	 --	 --	 --	
AS-AE*Dizziness	 1.15	(.91,	1.46)	 .85	(.67,	1.08)	 REF	
AS-AE*Drug	abuser	 --	 --	 --	
AS-AE*Drug	tolerance	 --	 --	 --	
AS-AE*Drug	
withdrawal	
syndrome	
9.50	(7.58,	
11.91)	
3.11	(2.46,	3.94)	 REF	
AS-AE*Elevated	mood	 --	 --	 --	
AS-AE*Euphoric	mood	 2.69	(1.25,	5.81)	 2.24	(1.11,	4.51)	 REF	
AS-AE*Fall	 1.11	(.84,	1.46)	 1.01	(.75,	1.35)	 REF	
AS-AE*Feeling	
abnormal	
1.15	(.90,	1.58)	 1.14	(.96,	1.60)	 REF	
AS-AE*Feeling	drunk	 1.24	(.34,	4.54)	 1.24	(.40,	3.90)	 REF	
AS-AE*Feeling	of	
relaxation	
--	 --	 --	
AS-AE*Gait	
disturbance	
.66	(.46,	.96)	 .67	(.46,	.96)	 REF	
AS-AE*Hallucination	 1.44	(.97,	2.14)	 1.05	(.69,	1.60)	 REF	
AS-AE*Auditory	
hallucination	
5.25	(1.86,	
14.76)	
4.12	(1.41,	
12.01)	
REF	
AS-AE*Visual	
hallucination	
1.06	(.48,	2.36)	 .89	(.38,	2.04)	 REF	
AS-AE*Mixed	
hallucination	
--	 --	 --	
AS-AE*Incoherence	 --	 --	 --	
AS-AE*Mood	altered	 1.05	(.53,	2.07)	 .98	(.50,	1.91)	 REF	
AS-AE*Off	label	use	 .77	(.57,	1.04)	 1.31	(1.00,	1.75)	 REF	
AS-AE*Somnolence	 1.45	(1.14,	1.85)	 .95	(.75,	1.21)	 REF	
AS-AE*Thinking	
abnormal	
1.27	(.77,	2.10)	 .76	(.43,	1.35)	 REF	
OR:	odds	ratio;	95%	CI:	95%	confidence	interval;	AS-AE:	abuse-specific	adverse	
event;	REF:	referent	group.	
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Note:	Missing	results	correspond	to	occasions	where	at	least	one	loglinear	
assumption	was	not	met.	
Boldface	indicates	a	significant	result.	
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CHAPTER	FIVE	
	
Discussion	and	Conclusions	
		
	 The	goal	of	this	dissertation	was	to	assess	the	etiology	and	prevalence	of	
gabapentin	misuse,	abuse,	and	diversion.	Though	gabapentin	was	initially	presumed	
to	have	limited	or	no	abuse	potential,9-13	which	may	have	contributed	to	its	
widespread	off-label	prescribing,	there	have	been	increasing	anecdotal	and	
published	reports	of	its	misuse	by	substance	abusers	in	the	community	and	penal	
system.	However,	to	date,	there	has	been	limited	systematic	evaluation	of	the	scope	
and	risk	of	gabapentin	misuse	and	its	associated	effects.	Further,	gabapentin	is	not	
controlled	under	the	Controlled	Substance	Act,	which	may	be	a	major	omission,	
given	that	its	close	structural	relative	pregabalin	is	considered	a	Schedule	V	drug	
(i.e.,	abuse	potential).16	As	such,	critical	insight	is	needed	to	better	assess	the	scope	
and	impact	of	the	risk	for	gabapentin	abuse.	
	 Specifically,	to	best	inform	policy-makers	and	prescribers	on	the	abuse	
potential	of	gabapentin,	it	is	necessary	to	examine	gabapentin	misuse,	abuse,	and	
diversion	in	a	multi-faced	approach,	namely	by	the	individual,	ecological,	and	
pharmacoepidemiological	factors	associated	with	this	phenomenon.	Due	to	the	
importance	of	conducting	theory-driven	epidemiological	research,23,24	an	adaptation	
of	the	Concurrent	Triangulation	Mixed	Method	Multilevel	Theoretical	Model25	was	
used	to	guide	the	dissertation.	Additionally,	the	proposed	methodology	took	
advantage	of	pre-existing	data	sources,	including	data	collected	from	two	NIH	
funded	cohorts;	published,	peer-reviewed	literature;	and	the	publicly-available	
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Federal	Adverse	Event	Reporting	System	data.	The	specific	aims	for	this	exploratory	
dissertation	project	were:	
1. To	describe	gabapentin	misuse	at	the	individual	level	among	an	existing	cohort	of	
drug	users	in	Appalachia.	There	is	a	significant	gap	in	what	is	known	about	how	
gabapentin	is	misused,	what	effects	make	it	desirable,	how	it	is	obtained	for	
recreational	purposes,	and	whether	it	has	“street	value.”		A	qualitative	analysis	was	
used	to	elucidate	the	individual	experience	of	obtaining	and	using	illicit	gabapentin,	
as	well	as	the	motivations	behind	and	effects	experienced	from	its	misuse.	
Individuals	were	recruited	from	two	existing	cohorts	of	active	drug	users	that	
indicated	recent	use	of	illicit	gabapentin	to	participate	in	focus	groups.	Survey	data	
relevant	to	gabapentin	misuse,	previously	collected	within	the	cohort	parent	
studies,	was	used	to	supplement	the	qualitative	data.	
2. To	estimate	the	prevalence	and	effects	of,	motivations	behind,	and	risk	factors	for	
gabapentin	misuse,	abuse,	and	diversion	ecologically.	To	date,	there	has	not	been	a	
systematic	assessment	or	assemblage	of	the	evidence	of	gabapentin	misuse,	abuse,	
and	diversion.	Further,	it	is	unknown	what	risk	factors	exist	for	gabapentin	abuse.	A	
thorough	review	was	conducted	of	existing	peer-reviewed	literature	on	illicit	
and/or	misused	gabapentin	to	estimate	the	prevalence	of	its	abuse	and	identify	
patterns	that	may	suggest	explicit	risk	for	abuse.	The	review	used	a	combination	of	
statistical	inference	and	qualitative	analysis	methods.		
3. To	evaluate	gabapentin	misuse	and	abuse	in	the	Federal	Adverse	Event	Reporting	
System	(FAERS)	using	traditional	and	innovative	pharmacovigilance	signal	measures.	
This	aim	drew	on	a	nationally	maintained,	publicly	available	dataset	of	drug	adverse	
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events	(AEs)	to	evaluate	the	association	between	AEs	indicative	of	misuse,	abuse,	
and	diversion	and	gabapentin.	Traditional	signal	measures	(i.e.,	proportional	
reporting	ratio,	reporting	odds	ratio,	information	component,	empirical	Bayes	
geometric	mean)	were	used	to	estimate	the	strength	of	association	between	a	
particular	AE	and	gabapentin.	A	novel	application	of	loglinear	modeling	was	also	
used	to	evaluate	the	association	between	co-reports	of	abuse	and	other	potential	
indicators	of	abuse	and	gabapentin,	which	were	compared	to	a	positive	and	negative	
control	(pregabalin	and	duloxetine,	respectively).	
Summary	of	findings	
	 Chapter	two	helped	to	characterize	and	explain	gabapentin	misuse	within	
two	substance	abuse	populations	in	Appalachian	Kentucky.	A	correlation	between	
gabapentin	misuse	and	nonmedical	prescription	opioid	use	was	found;	a	finding	
supported	by	other	recently	published	studies.15,32,34,42	Among	focus	group	
participants,	gabapentin	initiation	typically	followed	receiving	a	prescription	from	
their	doctor	for	an	off-label	use	(e.g.,	treatment	of	non-herpetic	pain),	which	could	
be	a	factor	in	facilitating	its	misuse.	Additionally,	several	long-term	drug	users	noted	
that	younger	people	were	misusing	gabapentin.	Though	no	information	was	
gathered	on	whether	young	drug	users	were	initiating	drug	use	with	gabapentin,	
this	could	be	a	likely	possibility	since	many	providers	are	unaware	of	its	widespread	
misuse	and	are	willing	to	prescribe	it.	This	is	an	important	area	for	further	
examination.	
	 Chapter	three	estimated	and	described	the	prevalence	and	effects	of,	
motivations	behind,	and	risk	factors	for	gabapentin	misuse,	abuse,	and	diversion	
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through	a	systematic	review	of	peer-reviewed	published	literature.	Thirty-three	
papers	were	included	in	the	study,	consisting	of	23	case	studies	and	11	
epidemiological	reports	from	seven	countries.	Population	prevalence	of	gabapentin	
misuse	was	reported	to	be	approximately	1%,	though	the	prevalence	is	much	higher	
within	populations	of	people	who	abuse	opioids	(15-22%).	Between	40-65%	of	
individuals	who	misuse	gabapentin	have	a	prescription.	The	review	identified	an	
array	of	subjective	experiences	reminiscent	of	opioids,	benzodiazepines,	and	
psychedelics	were	reported	over	a	range	of	doses,	including	those	with	clinical	
recommendations.	Gabapentin	was	misused	primarily	for	recreational	purposes,	
self-medication,	or	intentional	self-harm	and	was	misused	alone	or	in	combination	
with	other	substances,	especially	opioids,	benzodiazepines,	and/or	alcohol.	
Individuals	with	histories	of	drug	abuse	were	most	often	involved	in	its	misuse.	
	 Chapter	four	performed	a	post-marketing	pharmacovigilance	assessment	of	
FAERS	data	from	2005	to	2015.	Abuse-related	signals	were	identified	for	
gabapentin,	pregabalin,	and	duloxetine.	The	strongest	gabapentin-AE	signals	were	
found	with	ataxia,	drug	tolerance,	and	feeling	drunk;	these	signals	occurred	with	
pregabalin	as	well.	Examination	of	the	co-reporting	of	an	abuse-specific	AE	(AS-AE;	
e.g.,	substance	abuse)	and	a	possible	abuse	indicator	AE	(e.g.,	euphoria)	revealed	
that	co-endorsement	of	an	AS-AE	and	drug	withdrawal	syndrome,	AS-AE	and	
auditory	hallucinations,	AS-AE	and	delusions,	and	AS-AE	with	euphoric	mood	
occurred	with	significantly	higher	odds	for	both	gabapentin	and	pregabalin	
independently,	compared	to	duloxetine.	The	presence	of	abuse-related	signals	for	
gabapentin	is	important	for	regulatory	policy	and	providers	prescribing	gabapentin.	
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Limitations	
	 The	findings	from	this	dissertation	should	be	considered	in	light	of	several	
limitations,	described	in	detail	within	the	corresponding	chapter(s),	but	highlighted	
for	posterity	here.	Results	from	chapter	two	were	derived	solely	from	self-report,	
either	through	a	survey	or	through	conversation	in	the	focus	groups.	Chapter	three	
excluded	grey	literature	from	review,	which	may	have	contained	greater	detail	
about	risk	factors	for	and	results	of	gabapentin	misuse.	Lastly,	chapter	four	utilized	
the	FAERS	publicly	available	database,	which	has	a	very	low	spontaneous	reporting	
rate	and	may	not	reflect	experiences	from	the	larger	population.		
Conclusions	
In	spite	of	limitations,	this	dissertation	fills	a	critical	gap	in	the	literature,	
given	the	abundance	of	case	and	anecdotal	reports	of	widespread	gabapentin	abuse,	
but	no	rigorous	assessment	of	these	abuses.	Further,	there	has	been	limited	
understanding	of	what	may	contribute	to	gabapentin	misuse,	abuse,	and	diversion,	
as	well	as	identification	of	its	risk	factors.	Gabapentin,	when	used	appropriately,	is	
effective	for	its	indicated	uses	and	may	be	a	valuable	alternative	to	more	
problematic	opioid	analgesics;43	however,	we	must	first	understand	the	abuse	
potential	of	gabapentin	and	for	whom	it	may	be	counter-effective.		
It	is	clear	that	gabapentin	is	misused	for	a	variety	of	reasons	throughout	the	
United	States	and	internationally.	It	is	also	clear	that	due	to	continuous	claims	that	
gabapentin	has	no	abuse	potential,	providers	have	comfortably	prescribed	
gabapentin	off	label	for	many	disorders,	including	those	of	pain	and	drug	and	
alcohol	abuse.	While	gabapentin	may	be	effective	for	certain	non-approved	usages,	
 
 
	84	
widespread	off-label	prescribing	of	gabapentin	has	flooded	the	market	thereby	
facilitating	its	diversion.	Findings	from	the	studies	included	in	this	dissertation	
provide	definitive	evidence	of	the	following:	(1)	that	gabapentin	should	be	
prescribed	with	caution,	especially	for	individuals	with	a	history	of	substance	abuse,	
and	providers	should	be	aware	that	it	is	abused;	(2)	controlled	pharmacological	
experiments	are	needed	to	better	understand	and	characterize	gabapentin	
psychopharmacology	and	the	risks	associated	with	gabapentin	misuse;	and	(3)	a	
critical	reexamination	of	gabapentin’s	abuse	liability	and	regulation	are	warranted.		
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APPENDIX	A	
Systematic	review	search	queries	
PubMed	
(Gabapentin[supplementary	concept]	OR	
Gabapentin	OR	
Gralise	OR	
Neurontin	OR	
Horizant	OR	
Fanatrex)		
	
AND	
	
(Prescription	drug	misuse[MeSH]	OR	
Misuse	OR	
Abuse	OR	
Substance-related	Disorders	[MeSH]	OR	
Drug	Overdose[MeSH]	OR	
Overdose	OR	
Addict*	OR	
Dependen*	OR	
withdrawal)	
	
Web	of	Science	
(Gabapentin	OR	
Gralise	OR	
Neurontin	OR	
Horizant	OR	
Fanatrex)	
	
AND	
	
(Misuse	OR	
Abuse	OR	
Overdose	OR	
Addict*	OR	
Dependen*	OR	
withdrawal)	
	
CINAHL	
((MH	"Gabapentin")	OR	
gabapentin	OR	
Gralise	OR	
Neurontin	OR	
Horizant	OR	
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Fanatrex)	
	
AND	
	
((MH	“Substance	Abuse”)	OR	
“substance	abuse”	OR	
“misuse”	OR	
“abuse”	OR	
(MH	“Overdose”	OR)	
“overdose”	OR	
Addict*	OR	
Dependen*	OR	
withdrawal)	
	
PsycINFO	
(“Gabapentin”	OR	
“Gralise”	OR	
“Neurontin”	OR	
“Horizant”	OR	
“Fanatrex”)	
	
AND	
	
(DE	“Drug	Abuse”	OR	
DE	“Drug	Abuse	Prevention”	OR	
DE	“Drug	Overdoses”	OR	
“Abuse”	OR	
“Misuse”	OR	
“Overdose”	OR	
Addict*	OR	
Dependen*	OR	
withdrawal)		
	
Cochrane	
(gabapentin	OR		
Gralise	OR		
Neurontin	OR		
Horizant)	
	
AND	
	
(misuse	OR		
abuse	OR		
overdose	OR	
addict*	OR	
dependen*	OR	
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withdrawal)	
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